•determining the manner in which stockholders may send communications to our Board of Directors, as well as the process by which stockholder communications will be relayed to our Board of Directors and what our Board of Directors’ response, if any, should be;
•reviewing governance-related stockholder proposals and recommending our Board of Directors’ responses;
•reviewing and approving conflicts of interest of our directors and corporate officers, other than related personparty transactions reviewed by the Audit Committee; and
•reviewing and evaluating, at least annually, the performance of the CompensationNominating and Corporate Governance Committee and its members, including compliance of the Compensation Committee with its charter.
members.Our Nominating and Corporate Governance Committee operates under a written charter that satisfies the Nasdaq Rules. A copy of the charter of our nominating and corporate governance committee is available on our website at www.caredxinc.comwww.caredx.com in the Corporate Governance section of our Investors webpage. During fiscal year 2018,2020, our Nominating and Corporate Governance Committee held two meetingsone meeting and did not take any actions by written consent.
Science and Technology Committee
Our Science and Technology Committee is comprised of Fred E. Cohen, M.D., D. Phil, Grace E. Colón, Ph.D., Christine M. Cournoyer and Ralph Snyderman, M.D., each of whom is anon-employee member of our Board of Directors. In addition, Amy Abernethy, M.D., Ph.D. was appointed to our Science and Technology Committee on July 1, 2018 and served until her resignation from our Board of Directors on January 31, 2019. Dr. CohenColón is the
chair of our Science and Technology Committee. Our Science and Technology Committee is responsible for, among other things:
•meeting with the Company’s science and technology leaders to review the Company’s internal research and technology development activities and provideproviding input as it deems appropriate;
•reviewing technologies that the Company considers for licensing or acquisition;acquisition and
providing input as it deems appropriate;•reviewing the Company’s development of its technical goals and research and development strategies.
strategies and providing input as it deems appropriate;•periodically reporting to our Board of Directors regarding the Science and Technology Committee’s review and assessment of the Company’s internal technology development, technology assessment, technology review and technical goals and research and development strategies and any other matters as it deems appropriate; and
•reviewing and evaluating, at least annually, the performance of the Science and Technology Committee and its members.
Our Science and Technology Committee operates under a written charter. During fiscal year
2018,2020, our Science and Technology Committee held two meetings and did not take any actions by written consent.
Considerations in Evaluating Director Nominees
Our Nominating and Corporate Governance Committee uses a variety of methods for identifying and evaluating director nominees. In its evaluation of director candidates, our Nominating and Corporate Governance Committee will consider the composition of our Board of Directors, including, without limitation, issues of character, integrity, judgment, diversity, age, independence, skills, education, expertise, business acumen, business experience, length of service, understanding of our business and other commitments. Members of our Board of Directors are expected to prepare for, attend, and participate in all Board of Directors and applicable committee meetings. Our Nominating and Corporate Governance Committee requires the following minimum qualifications to be satisfied by any nominee for a position on our Board of Directors: (i) the highest personal and professional ethics and integrity, (ii) proven achievement and competence in the nominee’s field and the ability to exercise sound business judgment, (iii) skills that are complementary to those of the existing Board of Directors, (iv) the ability to assist and support management and make significant contributions to our success, and (v) an understanding of the fiduciary responsibilities that are required of a member of our Board of Directors and the commitment of time and energy necessary to diligently carry out those responsibilities. Other than the foregoing, there are no stated minimum criteria for director nominees, although our Nominating and Corporate Governance Committee may also consider such other factors as it may deem, from time to time, are in our and our stockholders’ best interests.
Although our Board of Directors does not maintain a specific policy with respect to board diversity, our Board of Directors believes that our Board of Directors should be a diverse body, and our Nominating and Corporate Governance Committee considers a broad range of backgrounds and experiences. In determining nominations of directors, our Nominating and Corporate Governance Committee may take into account the benefits of diverse viewpoints. Our Nominating and Corporate Governance Committee also considers these and other factors as it oversees the annual Board of Directors and committee evaluations. After completing its review and evaluation of director candidates, our Nominating and Corporate Governance Committee recommends to our full Board of Directors the director nominees for selection.
Stockholder Recommendations for Nominations to the Board of Directors
Our Nominating and Corporate Governance Committee will consider candidates for director recommended by stockholders holding at least one percent (1%) of the fully diluted capitalization of the Company continuously for at least 12 months prior to the date of the submission of the recommendation. Our Nominating and Corporate Governance Committee will evaluate such recommendations in accordance with its charter, our amended and restated bylaws,Bylaws, our policies and procedures for director candidates, as well as the regular director nominee criteria described above. This process is designed to ensure that our Board of Directors includes members with diversity of experience, skills and experience, including appropriate financial and other expertise relevant to our business. Stockholders wishing to recommend a candidate for nomination should contact our Corporate Secretary in writing. Such recommendations must include the candidate’s name, home and business contact information, detailed biographical data, relevant qualifications, a signed letter from the candidate confirming willingness to serve on our Board of Directors,
information regarding any relationships between the candidate and CareDx and evidence of the recommending stockholder’s ownership of our common stock. Such recommendations must also include a statement from the recommending stockholder in support of the candidate, particularly within the context of the criteria for Board of Directors’ membership. Our Nominating and Corporate Governance Committee has discretion to decide which individuals to recommend for nomination as directors.
A stockholder can nominate a candidate directly for election to our Board of Directors by complying with the procedures in Section 2.4(ii) of our
amended and restated bylawsBylaws and the rules and regulations of the SEC. Any eligible stockholder who wishes to submit a nomination should review the requirements in our
amended and restated bylawsBylaws on nominations by stockholders. Any nomination should be sent in writing to our Corporate Secretary at CareDx, Inc.,
3260 Bayshore Blvd., Brisbane, California 94005.1 Tower Place, 9th Floor, South San Francisco, CA 94080. To be timely for our
20202022 annual meeting of stockholders, our Corporate Secretary must receive the nomination no earlier than February
17, 202020, 2022 and no later than March
18, 2020.22, 2022. The notice must state the information required by Section 2.4(ii) of our
amended and restated bylawsBylaws and otherwise must comply with applicable federal and state law.
Communications with the Board of Directors
Stockholders wishing to communicate with our Board of Directors or with an individual member of our Board of Directors may do so by writing to our Board of Directors or to the particular member of our Board of Directors, and mailing the correspondence to our Chief Financial Officer at CareDx, Inc.,
3260 Bayshore Blvd., Brisbane,1 Tower Place, 9th Floor, South San Francisco, CA
94005.94080. Our Chief Financial Officer will review all incoming stockholder communications (excluding mass mailings, product complaints or inquiries, job inquiries, business solicitations and patently offensive or otherwise inappropriate material), and if deemed appropriate, the stockholder communications will be forwarded to the appropriate member or members of our Board of Directors, or if none is specified, to the
chairmanChairman of
our Board of Directors.the Board. This procedure does not apply to stockholder proposals submitted pursuant to
Rule 14a-8 under the Exchange Act.
Corporate Governance Guidelines and Code of Business Conduct and Ethics
Our Board of Directors has adopted Corporate Governance Guidelines. These guidelines address items such as the qualifications and responsibilities of our directors and director candidates and corporate governance policies
and standards applicable to us in general. In addition, our Board of Directors has adopted a Code of Business Conduct and Ethics that applies to all of our employees, officers and directors, including our Chief Executive Officer, Chief Financial Officer, and other executive and senior financial officers. The full text of our Corporate Governance Guidelines and our Code of Business Conduct and Ethics is posted on our website at www.caredx.com in the Corporate Governance section of our Investor Relations webpage. We intend to post any amendments to our Code of Business Conduct and Ethics, and any waivers of our Code of Business Conduct and Ethics for directors and executive officers, on the same website.
Clawback Policy
In April 2021, our Board of Directors adopted a compensation recovery (“clawback”) policy that provides that in the event we are required to restate our financial statements as a result of “material noncompliance” with the financial reporting requirements under the securities laws, or we determine that compensation paid to our current or former executive officers was awarded, paid or vested based on inaccurate financial statements or performance measurements, we can recover from our current and former executive officers any incentive-based compensation (including stock options) that is based on such material noncompliance or inaccurate financial information or performance measurements and received during the three-year period preceding the date on which we become required to prepare an accounting restatement or the three-year period preceding the date on which we determine that compensation paid to our current or former executive officers was awarded, paid or vested based on inaccurate financial statements or performance measurements, as applicable, subject to additional considerations that may be made by our Compensation Committee pursuant to the policy.
We intend to review the terms of our policy once the SEC adopts final regulations implementing Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act and, if necessary, will revise our policy to conform to such regulations.
Non-Employee Director Stock Ownership Policy
In April 2021, our Compensation Committee adopted a stock ownership policy that is applicable to each of our non-employee directors (excluding our Executive Chairman). Our Compensation Committee believes this policy is an important tool in aligning the interests of our non-employee directors with the long-term interests of our stockholders.
This policy requires that our non-employee directors hold shares of our common stock with a value equal to at least 300% of such director’s annual cash retainer for service on our Board of Directors (excluding service on any committee of our Board of Directors). For purposes of calculating ownership under this policy, the following sources are included: shares held in the director’s name; shares held in trust for the benefit of the director or his or her family; shares held by the director jointly with, or separately by certain family members of the director; shares held by the director through a profit sharing or savings plan; the “in the money” portion of vested, but unexercised, stock options or stock-settled stock appreciation rights; shares issued or vested pursuant to the achievement of the performance conditions of a performance-based equity award even if such shares are subject to additional time-based vesting requirements (the “Vested Performance Awards”); vested restricted stock unit awards; deferred share units; shares held by the director under any deferral plan; and restricted stock or phantom stock held by the director.
The following shares do not count towards the requirements: (i) shares that directors have the right to acquire through the exercise of stock options or stock appreciation rights that are not “in the money”, (ii) shares underlying stock options or stock appreciation rights that have not yet vested or (iii) shares that may be issued pursuant to unvested performance-based restricted stock units or other performance-based equity awards (other than Vested Performance Awards).
For purposes of these requirements, a director’s annual cash retainer shall be deemed to be the director’s annual cash retainer earned by such director for the calendar year immediately preceding the applicable date of calculation. To give our non-employee directors time to comply with our stock ownership policy, the policy provides that our non-employee directors have until the later of our 2024 annual meeting of stockholders or the first annual meeting of stockholders held after the date that is six years following their appointment as a director to comply with the stock ownership provisions in the policy.
Executive Officer Stock Ownership Policy
In April 2021, our Compensation Committee adopted a stock ownership policy that is applicable to each of our executive officers (including our Executive Chairman). Our Compensation Committee believes this policy is an important tool in aligning the interests of our executive officers with the long-term interests of our stockholders.
This policy requires that our executive officers hold shares of our common stock with a value equal to a multiple of his or her base salary, as follows: 3X in the case of our Chief Executive Officer and 1X in the case of each of our other executive officers. For purposes of calculating ownership under this policy, the following sources are included: shares held in the executive officer’s name; shares held in trust for the benefit of the executive officer or his or her family; shares held by the executive officer jointly with, or separately by certain family members of the executive officer; shares held by the executive officer through a profit sharing or savings plan; the “in the money” portion of vested, but unexercised, stock options or stock-settled stock appreciation rights; shares issued or vested pursuant to the achievement of the performance conditions of a performance-based equity award even if such shares are subject to additional time-based vesting requirements (the “Vested Performance Awards”); vested restricted stock unit awards; deferred share units; shares held by the executive officer under any deferral plan; and restricted stock or phantom stock held by the executive officer.
The following shares do not count towards the requirements: (i) shares that executive officers have the right to acquire through the exercise of stock options or stock appreciation rights that are not “in the money”, (ii) shares underlying stock options or stock appreciation rights that have not yet vested or (iii) shares that may be issued pursuant to unvested performance-based restricted stock units or other performance-based equity awards (other than Vested Performance Awards).
For purposes of these requirements, an executive officer’s base salary during any calendar year is deemed to be his or her base salary as of the close of business on December 31st of the immediately preceding year. To give our executive officers time to comply with our stock ownership policy, the policy provides that our executive officers have until the later of our 2024 annual meeting of stockholders or the first annual meeting of stockholders held after the date that is six years following the date such individual first becomes an executive officer to comply with the stock ownership provisions in the policy.
Recent Amendments to Equity Incentive Plans
In April 2021, our Compensation Committee adopted amendments (the “Equity Plan Amendments”) to the 2014 Plan, the CareDx, Inc. 2016 Inducement Equity Incentive Plan (the “2016 Inducement Plan”) and the CareDx, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan” and, together the 2014 Plan and the 2016 Inducement Plan, the “Equity Plans”) to provide, among other things, that we may not implement any “Exchange Program” under any of the Equity Plans without the approval of our stockholders, which includes option repricings and any exchange of awards granted under the
Equity Plans for awards of a different type or for cash. The Equity Plan Amendments also provide that all awards granted under each of the Equity Plans shall be subject to a minimum vesting schedule of at least one year following the date of grant of the award (or the date of commencement of employment or service, in the case of a grant made in connection with an award holder’s commencement of employment or service); however up to 5% of the shares of Common Stock authorized for issuance under the respective Equity Plan (other than any shares subject to awards issued to our executive officers) can be excluded from the minimum vesting period requirements.
Board of Directors’ Role in Risk Oversight
Risk is inherent with every business, and we face a number of risks, including strategic, financial, business and operational, legal and compliance, and reputational. We have designed and implemented processes to manage risk in our operations. Management is responsible for the
day-to-day management of risks we face, while our Board of Directors, as a whole and assisted by its committees, has responsibility for the oversight of risk management. In its risk oversight role, our Board of Directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are appropriate and functioning as designed.
Our Board of Directors believes that open communication between management and our Board of Directors is essential for effective risk management and oversight. Our Board of Directors meets with our Chief Executive Officer and other members of the senior management team at quarterly meetings of our Board of Directors, where, among other topics, they discuss strategy and risks facing the Company, as well as at such other times as they deemed appropriate.
While our Board of Directors is ultimately responsible for risk oversight, our board committees assist our Board of Directors in fulfilling its oversight responsibilities in certain areas of risk. Our Audit Committee assists our Board of Directors in fulfilling its oversight responsibilities with respect to risk management in the areas of internal control over financial reporting and disclosure controls and procedures, legal and regulatory compliance, and discusses with management and the independent auditor guidelines and policies with respect to risk assessment and risk management. Our Audit Committee also reviews our major financial risk exposures and the steps management has taken to monitor and control these exposures. In addition, our Audit Committee monitors certain key risks on a regular basis throughout the fiscal year, such as risk associated with internal control over financial reporting and liquidity risk. Our Nominating and Corporate Governance Committee assists our Board of Directors in fulfilling its oversight responsibilities with respect to the management of risk associated with board organization, membership and structure and corporate governance. Our Compensation Committee assesses risks created by the incentives inherent in our compensation policies. Finally, our full Board of Directors reviews strategic and operational risk in the context of reports from the management team, receives reports on all significant committee activities at each regular meeting, and evaluates the risks inherent in significant transactions.
Compensation Policy
Directors who are employees do not receive any additional compensation for their service on our Board of Directors. We reimburse our
non-employee directors for their reasonable
out-of-pocket costs and travel expenses in connection with their attendance at Board of Directors and committee
meetings.meetings in accordance with our travel policy. In
2018,2020, certain of our
non-employee directors received cash compensation, restricted stock unit awards and options to purchase shares of our common stock pursuant to our
2014 Equity Incentive Planoutside director compensation policy in effect during
20182020 as set forth below.
Our Executive Chair is an employee of ours and therefore is not subject to this policy.
Pursuant to our outside director compensation policy, our non-employee directors receivedreceive an annual retainer of $35,000$40,000 for their service on our Board of Directors (increased to $40,000 effective January 1, 2019).Directors. Members of our Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee and Science and Technology Committee, other than the chair of each such committee, receivedreceive an additional annual retainer of $10,000, $6,000, $5,000 and $5,000, respectively. The chair of our Audit Committee, Compensation Committee, Nominating and Corporate
Governance Committee and Science and Technology Committee each receivedreceive an additional annual retainer of $20,000, $12,000, $10,000 and $10,000, respectively. Additionally, thenon-employee individual acting as Chairman of our Board of Directors received an additional annual retainer of $30,000 (increased to $40,000 effective January 1, 2019). All annual retainers wereare paid quarterly andpro-rated for partial service in any year. Ournon-employee directors are entitled to elect the ratio of shares of common stock of the Company to cash issuable or payable to thenon-employee director for the payment of the annual retainers.
We will also continue to reimburse ournon-employee directors for their reasonableout-of-pocket costs and travel expenses in connection with their attendance at Board of Directors and committee meetings in accordance with our travel policy.
In addition, underon the first business day after each annual meeting of our outside director compensation policy in effect for 2018, nondiscretionary, automatic grants ofnon-statutory stock options and restricted stock units (“RSUs”) were made to ourstockholders, each non-employee directors. Anynon-employee director who first joinedcontinues to serve on our Board of Directors wasis automatically granted, on a nondiscretionary basis, an initial stock option to purchase 30,000 shares of our common stock having a grant date fair value of $100,000, rounded down to the nearest whole share, at an exercise price equal to the fair market value of our common stock on the grant date, of grant and an award of 10,000 RSUs. Eachrestricted stock units (“RSUs”) having a
great date fair value of
these options vests and become exercisable in equal monthly installments beginning with the first monthly anniversary after the grant date over the following three years, and each of these RSUs vests in three equal, annual installments beginning with the first annual anniversary after the grant. On the first business day after each annual meeting of our stockholders, eachnon-employee director who continued to serve on our Board of Directors was automatically granted an option to purchase an additional 15,000 shares of our common stock at an exercise price equal$100,000, rounded down to the
fair market value of our common stock on the date of grant and an award of 5,000 RSUs.nearest whole share. Each of these options vests and become exercisable in equal monthly installments beginning with the first monthly anniversary after the grant date over the following one year, and each of these RSUs vests in one installment on the one year anniversary of the grant date. The vesting of the options and the RSUs described above will accelerate in full upon a “change in
control”control,” as defined in our 2014
Equity Incentive Plan.
In addition, in January 2020, our Compensation Committee approved paying an additional annual retainer of $40,000 to our Lead Independent Director, which is the same retainer that was paid to our Lead Independent Director in connection with his service as the Chairman of our Board of Directors in 2019.
The following table sets forth the compensation accrued or paid by us to our non-employee directors during the year ended December 31, 2020, for service on our Board of Directors and its committees.
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| Name | | Fees
Earned
or Paid in Cash ($) | | Stock Awards ($)(1)(2) | | Option Awards ($)(3)(4) | | Total ($) |
| Michael D. Goldberg | | 146,000 | | | 99,975 | | | 77,665 | | | 323,640 | |
| George W. Bickerstaff, III | | 60,000 | | | 99,975 | | | 77,665 | | | 237,640 | |
| Fred E. Cohen, M.D., D. Phil | | 57,000 | | | 99,975 | | | 77,665 | | | 234,640 | |
| Grace E. Colón, Ph.D. | | 50,000 | | | 99,975 | | | 77,665 | | | 227,640 | |
| Christine M. Cournoyer | | 55,000 | | | 99,975 | | | 77,665 | | | 232,640 | |
| William A. Hagstrom | | 56,000 | | | 99,975 | | | 77,665 | | | 233,640 | |
| Ralph Snyderman, M.D. | | 50,000 | | | 99,975 | | | 77,665 | | | 227,640 | |
(1)The amounts in this column represent the fair value of common stock granted in lieu of cash retainers pursuant to our outside director compensation plan. Amounts represent the aggregate fair value of the stock awards computed as of the grant date of each stock award in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718. Our assumptions with respect to the calculation of these values are set forth in Note 14 of the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 that was filed with the SEC on February 24, 2021.
(2)As of December 31, 2020, each of our current non-employee directors held the following number of RSUs: Mr. Goldberg: 3,189; Mr. Bickerstaff: 3,189; Dr. Cohen: 3,189; Dr. Colón: 5,976; Ms. Cournoyer: 7,571; Mr. Hagstrom: 3,189; and Dr. Snyderman: 3,189.
(3)Amounts represent the aggregate fair value of the option awards computed as of the grant date of each option award in accordance with FASB ASC Topic 718. Our assumptions with respect to the calculation of these values are set forth in Note 14 of the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 that was filed with the SEC on February 24, 2021. There can be no assurance that option awards will be exercised (in which case no value will be realized by the individual) or that the value on exercise will approximate the fair value as computed in accordance with FASB ASC Topic 718.
(4)As of December 31, 2020, each of our current non-employee directors held options to purchase the following number of shares of common stock: Mr. Goldberg: 166,617; Mr. Bickerstaff: 71,318; Dr. Cohen: 24,129; Dr. Colón: 11,546; Ms. Cournoyer: 15,278; Mr. Hagstrom: 45,332; and Dr. Snyderman: 71,318.
Deferral Election Program
In December 2018,
theour Compensation Committee approved an RSU and performance unit deferral election program,
which is still in effect, pursuant to which our
non-employee directors, executive officers and certain other employees may elect, on an annual basis, to defer the settlement of all RSU and performance unit awards granted to such individuals
until the first to occur of (i) a “change in
control,” as defined in our 2014 Plan, (ii) the
individual’s death, or (iii) a specified number of years following
fiscal year, so that such awardsthe individual’s separation of service with us, in which case the shares will settle in a number of substantially equal annual installments selected by the individual, on every June 30 starting in the calendar year immediately following the year in which the individual incurs a separation of service.
The following table sets forth
Non-employee directors who elect to defer the
compensation accrued or paidsettlement of RSU and performance units must make these deferral elections by
us to ournon-employee directors during the
year ended December 31, 2018, for service on our Board of Directors and its committees. | | | | | | | | | | | | | | | | |
Name | | Fees Earned
or Paid in
Cash ($) | | | Stock
Awards
($)(1)(2) | | | Option
Awards
($)(3)(4) | | | Total ($) | |
Michael D. Goldberg | | | 40,373 | | | | 171,045 | | | | 117,250 | | | | 328,668 | |
George W. Bickerstaff, III | | | — | | | | 140,067 | | | | 117,250 | | | | 257,317 | |
Fred E. Cohen, M.D., D. Phil | | | 52,000 | | | | 73,700 | | | | 117,250 | | | | 242,950 | |
William A. Hagstrom | | | 34,004 | | | | 94,119 | | | | 117,250 | | | | 245,373 | |
Ralph Snyderman, M.D. | | | 9,203 | | | | 128,929 | | | | 117,250 | | | | 255,382 | |
Amy Abernethy, M.D., Ph.D.(5) | | | 3,765 | | | | 32,200 | | | | 26,347 | | | | 83,967 | |
(1) | The amounts in this column represent the fair value of common stock granted in lieu of cash retainers pursuant to our outside director compensation plan. Amounts represent the aggregate fair value of the stock awards computed as of the grant date of each stock award in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718. Our assumptions with respect to the calculation of these values are set forth in Note 14 of the consolidated financial statements included in our Annual Report on Form10-K for the year ended December 31, 2018.
|
(2) | As of December 31, 2018, each of our currentnon-employee directors held the following number of RSUs: Mr. Goldberg: 5,000; Mr. Bickerstaff: 5,000; Dr. Cohen: 5,000; Mr. Hagstrom: 5,000; and Dr. Snyderman: 5,000. Dr. Abernethy did not hold any RSUs as of December 31, 2018.
|
(3) | Amounts represent the aggregate fair value of the option awards computed as of the grant date of each option award in accordance with FASB ASC Topic 718. Our assumptions with respect to the calculation of these values are set forth in Note 14 of the consolidated financial statements included in our Annual Report on Form10-K for the year ended December 31, 2018. There can be no assurance that option awards will be exercised (in which case no value will be realized by the individual) or that the value on exercise will approximate the fair value as computed in accordance with FASB ASC Topic 718.
|
(4) | As of December 31, 2018, each of our currentnon-employee directors held options to purchase the following number of shares of common stock: Mr. Goldberg: 157,488; Mr. Bickerstaff: 62,189; Dr. Cohen: 47,189; Mr. Hagstrom: 61,203 and Dr. Snyderman: 76,787. Dr. Abernethy did not hold any options as of December 31, 2018.
|
(5) | Amy Abernethy, M.D., Ph.D. was appointed to our Board of Directors on July 1, 2018 and served until her resignation on January 31, 2019. Effective December 15, 2018, the Compensation Committee accelerated the vesting of 2,500 of Dr. Abernethy’s RSUs.
|
Effective April 18, 2019, the Compensation Committee approved an amendment and restatement of our outside director compensation policy (the “Amended Outside Director Compensation Policy”). Pursuant to the Amended Outside Director Compensation Policy, the equity award grants that each of ournon-employee directors is entitled to receive thereunder were amended to be as follows:
| 1. | Anynon-employee director who first joins our Board of Directors will be automatically granted an initial stock option to purchase shares of our common stock having a grant date fair value of $150,000, rounded down to the nearest whole share, at an exercise price equal to the fair market value of our common stock on the date of grant and an award of RSUs having a grant date fair value of $150,000, rounded down to the nearest whole share. Consistent with our outside director compensation policy in effect for 2018, each of these options will vest and become exercisable in equal monthly installments beginning with the first monthly anniversary after the grant date over the following three years, and each of these RSUs will vest in three equal, annual installments beginning with the first annual anniversary after the grant.
|
| 2. | On the first business day after each annual meeting of our stockholders, eachnon-employee director who continues to serve on our Board of Directors will be automatically granted an option to purchase shares of our common having a grant date fair value of $100,000, rounded down to the nearest whole share at an exercise price equal to the fair market value of our common stock on the date of grant and an award of RSUs having a grant date fair value of $100,000, rounded down to the nearest whole share. Consistent with our outside director compensation policy in effect for 2018, each of these options will vest and become exercisable in equal monthly installments beginning with the first monthly anniversary after the grant date over the following one year, and each of these RSUs will vest in one installment on the one year anniversary of the grant date.
|
Also consistent with our outside director compensation policy in effect for 2018, the vestingend of the options andcalendar year preceding the RSUs described above will accelerate in full upon a “change in control” as defined in our 2014 Equity Incentive Plan.
All other termsdate of the Amended Outside Director Compensation Policy, includinggrant of the cash retainer amounts disclosed above, are unchanged fromstock award (or on such earlier date as specified by the compensation provided to ournon-employee directors in 2018.
Equity Compensation Plan Information
The following table provides information asCompany). As of December 31, 20182020, none of our non-employee directors held any deferred stock awards.
Not only does the RSU and performance unit deferral election program allow our eligible participants to defer the federal income taxes otherwise payable upon the delivery of RSUs, but our Compensation Committee also believes that with respect to sharesnon-employee directors and executives who avail themselves of the deferral features, such person will necessarily hold Company stock for a longer period of time. Accordingly, any deferred RSUs will continue to align such portion of our common stock that maynon-
employee directors and named executive officers’ compensation with the interests of our stockholders for a longer period of time than would be
issued under our existing equity compensation plans. | | | | | | | | | | | | |
Plan Category | | (a)
Number of
Securities to be
Issued Upon
Exercise of
Outstanding
Options,
Warrants and
Rights | | | (b)
Weighted
Average
Exercise Price of
Outstanding
Options,
Warrants and
Rights(1) | | | (c)
Number of
Securities
Remaining
Available for
Future Issuance
Under Equity
Compensation
Plans (Excluding
Securities
Reflected in
Column (a)) | |
Equity compensation plans approved by stockholders(2) | | | 3,406,631 | | | $ | 9.15 | | | | 287,490 | |
Equity compensation plans not approved by stockholders(3) | | | 62,790 | | | $ | 4.48 | | | | 34,687 | |
Total: | | | 3,469,421 | | | | N/A | | | | 322,177 | |
(1) | The weighted average exercise price is calculated based solely on outstanding stock options and warrants and does not reflect the shares that will be issued upon the vesting of outstanding awards of RSUs, which have no exercise price.
|
(2) | Includes the following plans: CareDx, Inc. 1998 Equity Incentive Plan, CareDx, Inc. 2008 Equity Incentive Plan, ImmuMetrix 2013 Equity Incentive Plan, the 2014 Plan and the CareDx, Inc. 2014 Employee Stock Purchase Plan (“ESPP”). Our 2014 Plan provides that on the first day of each fiscal year beginning in 2015, the number of shares available for issuance thereunder is automatically increased by a number equal to the least of (i) four percent (4.0%) of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year, or (ii) such other amount as may be determined by our Board of Directors. Our ESPP provides that on the first day of each fiscal year beginning in 2015, the number of shares available for issuance thereunder is automatically increased by a number equal to the least of (i) 133,900 shares of common stock, (ii) one andone-half percent (1.5%) of the outstanding shares of Common Stock on the last day of the immediately preceding fiscal year, or (iii) such other amount as may be determined by our Board of Directors. On January 1, 2019, the number of shares available for issuance under our 2014 Plan and our ESPP increased by 1,655,398 shares and 133,900 shares, respectively, pursuant to these provisions. These increases are not reflected in the table above.
|
(3) | Consists of shares available for issuance under the CareDx, Inc. 2016 Inducement Equity Incentive Plan.
|
provided by typical vesting periods.
RATIFICATION OF APPOINTMENT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Our Audit Committee has appointed Deloitte & Touche LLP (“Deloitte”Deloitte”) as our independent registered public accounting firm to audit our consolidated financial statements for our fiscal year ending December 31, 2019.2021. Deloitte also served as our independent registered public accounting firm for our fiscal year ended December 31, 2020. Deloitte was appointed as our independent registered public accounting firm on April 10, 2018. At the Annual Meeting, stockholders are being asked to ratify the appointment of Deloitte as our independent registered public accounting firm for our fiscal year ending December 31,
2019.2021. Stockholder ratification of the appointment of Deloitte is not required by our
amended and restated bylawsBylaws or other applicable legal requirements. However, our Board of Directors is submitting the appointment of Deloitte to our stockholders for ratification as a matter of good corporate governance. In the event that this appointment is not ratified by the affirmative vote of a majority of the shares present
in personvirtually or by proxy at the Annual Meeting and entitled to vote, such appointment will be reconsidered by our Audit Committee. Even if the appointment is ratified, our Audit Committee, in its sole discretion, may appoint another independent registered public accounting firm at any time during our fiscal year ending December 31,
20192021 if our Audit Committee believes that such a change would be in the best interests of CareDx and its stockholders. A representative of Deloitte is expected to be present at the Annual Meeting, will have an opportunity to make a statement if he or she wishes to do so and is expected to be available to respond to appropriate questions from stockholders.
Changes in Independent Registered Public Accounting Firm
On April 10, 2018, the Audit Committee dismissed Ernst & Young LLP (“EY”) as our independent registered public accounting firm.
The reports of EY on our consolidated financial statements for the fiscal years ended December 31, 2017 and 2016 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that the report of EY on our consolidated financial statements for the fiscal year ended December 31, 2016 contained an explanatory paragraph describing conditions that raise substantial doubt about our ability to continue as a going concern.
During the fiscal years ended December 31, 2017 and 2016 and the subsequent interim period through April 10, 2018, there have been no “disagreements” (as defined in Item 304(a)(1)(iv) of RegulationS-K and related instructions) with EY on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of EY, would have caused EY to make reference thereto in their reports on the consolidated financial statements for such fiscal years.
During the fiscal years ended December 31, 2017 and 2016 and any subsequent interim period through April 10, 2018, there have been no “reportable events” (as defined in Item 304(a)(1)(v) of RegulationS-K), except that, as of December 31, 2016, we identified the following four material weaknesses in our internal control over financial reporting relating to: (i) certain areas of our financial statement close process, specifically with respect to an incorrect classification of the deferred consideration payable to the former majority shareholders of CareDx International AB (“CareDx International AB”), within our statement of cash flows following the CareDx International AB acquisition, ensuring that our bonus accrual and contingent liability balances were accurate, ensuring the proper application of foreign exchange rates in our consolidation process, and ensuring the proper review of terms and conditions of a debt agreement, (ii) a failure to design and implement transaction level or management review controls for the oversight, integration and consolidation of the acquired entities or controls to assess the completeness and accuracy of information, including key inputs and assumptions used by third party specialists, used in estimating the fair value of assets acquired and liabilities assumed, (iii) a failure to properly apply the revenue recognition criteria to certain contractual arrangements with payers, specifically with respect to
controls over the proper analysis and review of the terms and conditions of contractual arrangements and controls over the review of our aged accounts receivables, and (iv) a failure in the design and implementation of controls over our accounting for inventory overhead absorption. We remediated each of these material weaknesses as of December 31, 2017.
We provided EY with a copy of the disclosure set forth in Item 4.01 of the Current Report on Form8-K that was filed with the SEC on April 16, 2018 (the “Form8-K”) and requested that EY furnish us with a copy of its letter addressed to the SEC, pursuant to Item 304(a)(3) of RegulationS-K, stating whether or not EY agrees with the statements related to them made by us in the Form8-K. A copy of EY’s letter to the SEC dated April 16, 2018 was filed as Exhibit 16.1 to the Form8-K.
On April 10, 2018, the Audit Committee approved the appointment of Deloitte as our new independent registered public accounting firm, effective immediately. During the fiscal years ended December 31, 2017 and 2016 and the subsequent interim period through April 10, 2018, neither we, nor anyone on our behalf, consulted Deloitte regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on our financial statements , and no written report or oral advice was provided to us by Deloitte that Deloitte concluded was an important factor considered by us in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a “disagreement” (as defined in Item 304(a)(1)(iv) of RegulationS-K and the related instructions) or a “reportable event” (as that term is defined in Item 304(a)(1)(v) of RegulationS-K).
Fees Paid to the Independent Registered Public Accounting Firm
The following table presents fees for professional audit services and other services rendered to us for our fiscal year ended December 31,
20182020 and 2019 by Deloitte,
and for our fiscal year ended December 31, 2017 by EY, in each case, our principal independent registered public accounting firm for such period.
| | | | | | | | |
| | | 2018 | | | 2017 | |
Audit Fees(1) | | $ | 1,182,800 | | | $ | 2,335,000 | |
Audit-Related Fees(2) | | | 95,000 | | | | — | |
Tax Fees(3) | | | 147,000 | | | | — | |
All Other Fees(4) | | | 3,790 | | | | 2,000 | |
| | | | | | | | |
| | $ | 1,428,590 | | | $ | 2,337,000 | |
| | | | | | | | |
(1) | Audit Fees include fees andout-of-pocket expenses, whether or not yet invoiced, for professional services associated with the annual audit of our financial statements, the reviews of our interim financial statements, the issuance of consents and comfort letters in connection with registration statement filings with the SEC.
|
(2) | Audit-Related Fees consist of fees for other audit-related professional services. In 2018, this fee included review of accounting for new debt and new license agreement.
|
(3) | Tax Fees include fees for corporate tax advisory.
|
(4) | All Other Fees include any fees billed that are not audit, audit related or tax fees. These fees were for an online accounting literature database.
|
| | | | | | | | | | | | | | |
| | 2020 | | 2019 |
Audit Fees(1) | | $ | 1,749,926 | | | $ | 1,843,079 | |
Audit-Related Fees(2) | | 306,684 | | | 20,000 | |
Tax Fees(3) | | 54,075 | | | 42,000 | |
All Other Fees(4) | | 1,895 | | | 3,790 | |
| Total | | $ | 2,112,580 | | | $ | 1,908,869 | |
(1)Audit Fees include fees and out-of-pocket expenses, whether or not yet invoiced, for professional services associated with the annual audit of our financial statements, the reviews of our interim financial statements, statutory audits and reviews of accounting for acquisitions in 2019 and collaboration agreements in 2019 and 2020.
(2)Audit-Related Fees consist of fees for other audit-related professional services. These fees included the issuance of consents and comfort letters in connection with public offerings and registration statement filings with the SEC, and reviews of SEC comment letters.
(3)Tax Fees include fees for corporate tax advisory.
(4)All Other Fees include any fees billed that are not audit, audit related or tax fees. These fees were for an online accounting literature database.
In
2018,2020, there were no other professional services provided by Deloitte that would have required our Audit Committee to consider their compatibility with maintaining the independence of Deloitte.
Audit Committee Policy on
Pre-Approval of Audit and Permissible
Non-Audit Services of Independent Registered Public Accounting Firm
Our Audit Committee has established a policy governing our use of the services of our independent registered public accounting firm. Under the policy, our Audit Committee is required topre-approve all audit and
permissiblenon-audit services performed by our independent registered public accounting firm to ensure that the provision of such services does not impair such accounting firm’s independence. The policy generallypre-approves specified services in the defined categories of audit services, audit-related services, tax services and other services up to specified amounts. Thepre-approval of services may be delegated to one or more of the Audit Committee’s members, but the decision must be reported to the full Audit Committee at its next scheduled meeting. In the years ended December 31, 20182020 and 2017,2019, services and related fees identified above under
the captions “Audit Fees,” “Audit-Related Fees,” “Tax Fees,” and “All Other Fees” that were billed by
either Deloitte
or EY were approved by the Audit Committee in accordance with SEC requirements.
Vote Required; Board Recommendation
and Vote The ratification of the appointment of Deloitte requires the affirmative vote of a majority of the shares of our common stock present
in personvirtually or by proxy at the Annual Meeting and entitled to vote thereon. Abstentions will have the effect of a vote AGAINST the proposal.
Broker non-votes will have no effect on this proposal.
OUR BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE RATIFICATION OF THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2019.2021.
The information contained in the following Audit Committee Report shall not be deemed to be soliciting material or to be filed with the Securities and Exchange Commission, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that CareDx, Inc. (the “Company”“Company”) specifically incorporates it by reference in such filing. The Audit Committee has reviewed and discussed the Company’s audited consolidated financial statements with management and Deloitte & Touche LLP (“Deloitte”Deloitte”), the Company’s independent registered public accounting firm. The Audit Committee has discussed with Deloitte the matters required to be discussed by Auditing Standard No. 1301, “Communications with Audit Committees”the applicable requirements of the Public Company Accounting Oversight Board.Board and the SEC.
The Audit Committee has received and reviewed the written disclosures and the letter from Deloitte required by the applicable requirements of the Public Company Accounting Oversight Board regarding Deloitte’s communications with the Audit Committee concerning independence, and has discussed with Deloitte its independence.
Based on the review and discussions referred to above, the Audit Committee recommended to the Board of Directors that the Company’s audited consolidated financial statements be included in the Company’s Annual Report on
Form 10-K for the fiscal year ended December 31,
20182020 for filing with the Securities and Exchange Commission.
Respectfully submitted by the members of the Audit Committee of the Board of Directors:
George Bickerstaff (Chair)
Christine M. Cournoyer
William A. Hagstrom
PROPOSAL NO. 3
ADVISORY VOTE ON EXECUTIVE COMPENSATION
Pursuant to the proxy rules under the Exchange Act and as required by Section 951 of the Dodd-Frank Wall Street Reform and Consumer Protection Act, we are presenting to our stockholders with a non-binding, advisory vote to approve the compensation of our named executive officers as described in this proxy statement. This proposal is commonly referred to as a “say-on-pay” proposal.
The compensation of our named executive officers is designed to attract, motivate and retain talented and experienced executives, who are critical to our success. Our executive compensation contains elements of cash and equity-based compensation. Our Board of Directors and our Compensation Committee believe that our executive compensation directly and substantially link rewards to measurable corporate performance and are designed to align the interests of our named executive officers with those of our stockholders and to reward our named executive officers for the achievement of our near-term and longer-term financial and strategic goals. The process for determining compensation packages requires that our Board of Directors and our Compensation Committee use judgment and experience to determine the optimal components and amounts of compensation for each named executive officer.
The say-on-pay vote gives you as a stockholder the opportunity to express your views regarding the compensation of our named executive officers by voting to approve or not approve such compensation as described in this proxy statement. This vote is advisory and will not be binding upon our Board of Directors or our Compensation Committee. However, our Board of Directors and our Compensation Committee value the opinion of our stockholders and will take into account the outcome of the vote when considering future executive compensation arrangements. The vote on this resolution is not intended to address any specific element of compensation, but rather relates to the overall compensation of our named executive officers, as described in this proxy statement in accordance with the compensation disclosure rules of the SEC.
We encourage our stockholders to read the “Executive Compensation” section in this proxy statement, including the compensation tables and the related narrative disclosure, which describes the structure and amounts of the compensation of our named executive officers in fiscal year 2020.
Vote Required; Board Recommendation
The advisory approval of this Proposal No. 3 requires the affirmative vote of a majority of the shares of our common stock present virtually or by proxy at the Annual Meeting and entitled to vote thereon. Abstentions will have the effect of a vote AGAINST the proposal. Broker non-votes will have no effect on this proposal. Although this vote is advisory in nature and does not impose any action on our Board of Directors or our Compensation Committee, we strongly encourage all stockholders to vote on this matter.
OUR BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS
AS DISCLOSED IN THIS PROXY STATEMENT.
PROPOSAL NO. 4
APPROVAL OF AMENDMENTS TO THE COMPANY’S CERTIFICATE OF INCORPORATION AND BYLAWS TO ELIMINATE CERTAIN SUPERMAJORITY VOTING REQUIREMENTS
Our Certificate of Incorporation currently provides that certain provisions thereof may only be amended, altered or repealedby the affirmative vote of the holders of at least 662⁄3% (a “Supermajority”) of the voting power of all outstanding shares of common stock entitled to vote generally in the election of our directors. Similarly, the Bylaws require a Supermajority of the voting power of our outstanding voting securities, voting together as a single class, to amend the Bylaws. Our Board of Directors has approved and recommends that our stockholders adopt amendments to our Certificate of Incorporation and Bylaws to eliminate these Supermajority voting requirements. The descriptions in this Proposal No. 4 of the proposed amendments to the Certificate of Incorporation and the Bylaws are qualified in their entirety by, and should be read in conjunction with, the actual text of the changes to each document that would be implemented upon stockholder approval of this Proposal No. 4 that are marked in Articles VI and IX of the Certificate of Incorporation attached as Appendix A and in Article X of the Bylaws attached as Appendix B.
Reason for Approving the Amendments to the Certificate of Incorporation and Bylaws
Article IX of the Certificate of Incorporation currently provides that amendments to certain provisions of our Certificate of Incorporation must be approved by a Supermajority of the voting power of all outstanding shares of common stock entitled to vote generally in the election of our directors. Similarly, the Bylaws require a Supermajority of the voting power of our outstanding voting securities, voting together as a single class, to amend the Bylaws, and the Certificate of Incorporation also provides that a Supermajority of the voting power of our stock entitled to vote thereon is required for our stockholders to amend, alter or repeal the Bylaws or adopt new bylaws. We established the Supermajority voting requirements at the time of our initial public offering to protect the interests of our stockholders by ensuring that fundamental changes to the Certificate of Incorporation and Bylaws have the support of a broad consensus of all stockholders. Since certificates of incorporation often set forth rights and privileges of stockholders, some view supermajority voting restrictions on the ability to amend a certificate of incorporation as a limitation on stockholder rights. After considering the advantages and disadvantages of the Supermajority voting requirements, including through review of current governance best practices, our Board of Directors has determined that it is in the best interests of the Company and our stockholders to amend the Certificate of Incorporation and Bylaws to eliminate the Supermajority voting requirements with respect to amendments to the Certificate of Incorporation and Bylaws. However, our Board of Directors has not approved, and is not asking stockholders to approve at this time, removal of the supermajority voting provision with respect to the threshold required to remove our directors as set forth in Article V of the Certificate of Incorporation. Because approval of a majority of the voting power of the Company would still be required to effect action under the revised provisions, our Board of Directors believes this amendment affords sufficient protection of stockholder interests while being responsive to the prevailing views regarding best corporate governance practices.
If approved, stockholder-approved amendments to the Certificate of Incorporation would not be subject to a Supermajority vote and instead would require the affirmative vote of a majority of the voting power of all outstanding shares of common stock entitled to vote generally in the election of our directors, and stockholder-approved amendments to the Bylaws would not be subject to a Supermajority vote and instead would require the affirmative vote of a majority of the voting power of our outstanding voting securities, voting together as a single class.
Vote Required; Board Recommendation
The approval of amendments to the Certificate of Incorporation and Bylaws to eliminate certain supermajority voting requirements with respect to amendments thereof requires an affirmative vote of 662⁄3% of the voting power of all outstanding shares of our common stock entitled to vote generally in the election of our directors. Abstentions will have the effect of a vote AGAINST the proposal. Broker non-votes will be counted as votes against proposal. If this Proposal No. 4 is approved by our stockholders, we intend to promptly file the amendment to the Certificate of Incorporation with the changes to Articles VI and IX as set forth on Appendix A with the Secretary of State of the State of Delaware, and to adopt Amended and Bylaws with the changes to Article X as set forth on Appendix B.
OUR BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” THE APPROVAL OF AMENDMENTS TO THE CERTIFICATE OF INCORPORATION AND BYLAWS TO ELIMINATE CERTAIN SUPERMAJORITY VOTING REQUIREMENTS.
EXECUTIVE OFFICERS
The following table identifies certain information about our executive officers as of April 30,
2019. Each executive officer serves at the discretion of our Board of Directors and holds office until his or her successor is duly elected and qualified or until his or her earlier resignation or removal.2021. There are no family relationships among any of our directors or executive officers.
| | | | | | | | | | | | | | |
Name | | Age | | | Position(s) |
Peter Maag, Ph.D. | | 54 | 52 | | | Chief Executive OfficerChair and Director |
Reginald Seeto, MBBS | | 49 | 47 | | | President and Chief BusinessExecutive Officer |
Michael Bell
Ankur Dhingra | | 45 | 50 | | | Chief Financial Officer |
Sasha King, M.B.A. | | 35 | 33 | | | Chief CommercialMarketing Officer |
James P. Yee, M.D., Ph.D.
| | | 69 | | | Chief Medical Officer |
Peter Maag, Ph.D.For a brief biography of Dr. Maag, please see “BOARD OF DIRECTORS AND CORPORATE GOVERNANCE—Continuing Directors.”
Reginald Seeto, MBBS has served as our President and Chief Business Officer since November 2018.MBBS. For a brief biography of Dr. Seeto, served as the Chief Operating Officer of Ardelyx, Inc., a specialized biopharmaceutical company, from October 2016 throughplease see “BOARD OF DIRECTORS AND CORPORATE GOVERNANCE—Continuing Directors.”
mid-AugustAnkur Dhingra 2018 and continued with Ardelyx, Inc. from August 2018 through December 2018 as a consultant. From April 2008 until October 2016, Dr. Seeto held various positions of increasing responsibility at MedImmune Limited, a biotechnology company and subsidiary of AstraZeneca Plc, and at AstraZeneca, most recently serving as vice president, head of partnering and strategy for AstraZeneca. Earlier, he served as company president of AstraZeneca Thailand and before that, as executive vice president of corporate development and strategy for MedImmune. Prior to joining AstraZeneca/MedImmune, Dr. Seeto held senior marketing roles at Organon Biosciences, which was acquired by Schering Plough in 2007, and Boehringer Ingelheim Pharmaceuticals. Earlier, Dr. Seeto served as an engagement manager for McKinsey & Company and started his career as a practicing medical doctor and clinical researcher in Australia. Dr. Seeto earned both his B.S. and MBBS in medical studies from the University of Sydney, Australia.Michael Bell has served as our Chief Financial Officer since April 2017. He has over 20March 2021. Prior to joining CareDx, Mr. Dhingra served the last 18 years at Agilent Technologies, Inc., a provider of internationalanalytical and diagnostics tools and services, in a number of finance and accounting experience. Frombusiness leadership positions, including Vice President – Investor Relations, from January 20162019 to March 2017,2021, and Vice President – Group CFO, Life Sciences and Applied Markets, from May 2015 to December 2019. Mr. Bell served as the Chief Financial OfficerDhingra also sits on Advisory Board of Metabiota,Arcus Lending Inc., a San Francisco-based company that develops and sells risk analytics products focused on infectious disease. From May 2012 to January 2016, he served as the Chief Financial Officer of Singulex, Inc., a clinical diagnostics company. Prior to that,an independent mortgage banker. Mr. Bell held leadership and executive positions within Novartis, including with Novartis Diagnostics, a global provider of blood screening solutions, where he served as Chief Financial Officer from 2011 to 2012, and Senior Director, Global Head of Finance from 2008 to 2011. Mr. Bell also previously worked for several years in public accounting with both Ernst & Young LLP and Deloitte, UK. He holds a Bachelor of Science degree in Mathematics with Computing from the University of Leicester in the United Kingdom, andDhingra is a Fellowmember of the Institute of Chartered Accountants in England & Wales.
of India.
Sasha King, M.B.A. has served as our Chief Marketing Officer since June 2019. Prior to that, she served as our Chief Commercial Officer sincefrom October 2017.2017 to June 2019. Ms. King brings over 10 years of diagnostics and genetic testing experience. Prior to becoming our Chief Commercial Officer, she served as our Ad Interim Chief Commercial Officer from June to October 2017 and as our Head of Marketing from March to June 2017. From August 2015 to March 2017, she worked in companion diagnostics marketing at Genentech, and was a sales leader at Ariosa Diagnostics from July 2013 to August 2015. While at Genentech, she worked on the launch of the first FDA approved cell free DNA test in oncology, thePD-Ll test launch, and the Foundation Medicine partnership. Ms. King was an early member of the commercial team at Ariosa, a leader in the field of noninvasive prenatal testing, (“NIPT”), which is now part of the Roche Group. She led the launch of their test into Asia Pacific and Canada. From August 2008 to July 2011, Ms. King worked at Fletcher Spaght, a life science consulting and venture capital fund. She received a bachelor of science in bioengineering from Massachusetts Institute of Technology in 2008 and an M.B.A. from Stanford Graduate School of Business in 2013.
James P. Yee, M.D., Ph.D. has served as our Chief Medical Officer since August 2006. Dr. Yee brings more than 25 years of research and development experience. Prior to CareDx, Dr. Yee served as Vice President and Head of Development for Celera Genomics from January 2003 to June 2006, where he built the development organization at Celera South San Francisco and led clinical research and therapeutic development activities for cancer and immune-mediated inflammatory diseases. Prior to his work at Celera, Dr. Yee served as Vice President of Clinical andPre-Clinical Research for the Inflammatory and Viral Diseases Unit at Roche Pharmaceuticals from June 1995 to December 2002. In this role, he led the team responsible for selecting and evaluating compounds for clinical drug development and oversaw groups responsible for toxicology, drug metabolism, pharmacokinetics, bioanalytical chemistry, analytical chemistry, formulations, regulatory affairs, project management, and clinical research. Earlier in his career, Dr. Yee held a variety of research and development positions of increasing responsibility at Syntex Corporation, including Vice President and Director of the Institute for Clinical Medicine. Dr. Yee received his bachelor’s degree from the University of California at Berkeley in electrical engineering and computer science. Dr. Yee went on to earn a PhD in biophysics at University of California at Berkeley. He attended the University of California, Los Angeles School of Medicine, where he earned his medical degree, and he is board certified in internal medicine.
Legal Proceedings with Executive Officers
There are no legal proceedings related to any of the executive officers whichthat require disclosure pursuant to Items 103 or 401(f) ofRegulation S-K.
EXECUTIVE COMPENSATION
Our
Compensation Discussion and Analysis
In this Compensation, Discussion and Analysis (“CD&A”), we provide an overview of our executive compensation philosophy and objectives, as well as a description of the material components of our executive compensation program. This CD&A is intended to be read in conjunction with the tables that immediately follow this section, which provide further historical compensation information.
As of December 31, 2020, the following executive officers constituted our Named Executive Officers (collectively, our “NEOs”):
| | | | | | | | |
| Name | | Position(s) |
Peter Maag, Ph.D.(1) | | Executive Chair and former Chief Executive Officer |
Reginald Seeto, MBBS(2) | | President, Chief Executive Officer and former Chief Business Officer |
| Sasha King, M.B.A | | Chief Marketing Officer |
Michael Bell(3) | | Former Chief Financial Officer |
Marcel Konrad, M.B.A.(4) | | Former Interim Chief Financial Officer |
(1)Effective November 1, 2020, Dr. Maag transitioned from Chief Executive Officer to Executive Chair.
(2)Effective November 1, 2020, Dr. Seeto transitioned from Chief Business Officer to Chief Executive Officer.
(3)Mr. Bell resigned effective December 31, 2020.
(4)Mr. Konrad was appointed as our Interim Chief Financial Officer effective December 31, 2020 and served in this role until March 25, 2021.
I.Executive Summary
2020 Business Highlights
Over the course of 2020, we furthered our growth in the healthcare solutions market by leveraging our innovative testing services, products and digital tools. To date, we have devoted substantially all of our efforts to product development, increasing revenue and continuing innovation. 2020 was an important year for CareDx as we achieved the following:
Financials and Performance
• Increased our revenue to $192.2 million, an increase of 51% compared to 2019
• Provided approximately 79,000 patient results in 2020 compared to 49,000 in 2019
• Strengthened Balance Sheet to $224.7 million of cash, cash equivalents and marketable securities through our At-the- Market facility of $23.5 million and a June 2020 Public Offering with proceeds of $134.6 million
New Business and Expansion
• Launched new offering AlloCell for allogenic cell therapy
• Received CE Marking for AlloSeqTx17 and AlloSeqcfDNA products
• Received Medicare reimbursement pricing for AlloSure Heart
Response to COVID-19
• Launched RemoTrac, a remote home-based blood draw solution using mobile phlebotomy to enable immune compromised transplant patients to continue to have their blood drawn safely during the COVID-19 pandemic
• Launched AlloCare, a transplant specific smartphone app developed in conjunction with transplant patients and physicians
• Launched the International COVID-19 registry
Pipeline Progression and Partnership
• AlloSure Lung submitted to MolDx
• Multimodality partnership with Veracyte, Inc. to develop HistoMap
• Multimodality partnership with Weill Cornell Medicine on the UroMap offering
In achieving the above, we have continued to execute on our business objectives, improving our products and technologies, and strengthening our financial position.
Further, our long-term total stockholder return (“TSR”) has outperformed our competitors over the long-term:
Key 2020 Compensation Decisions
Aligned with our accomplishments in 2020 and strong business and company performance as outlined above, we took certain actions related to our compensation program. Specifically, with respect to long-term incentives, we sought to add more “at-risk” pay for our executives while balancing retention needs and building share ownership among our executives. Beginning in 2019, we added performance-based incentives to our compensation mix for executives, strengthening the pay-for-performance relationship and driving fulfillment of key strategic goals. We continue to manage award design, with a goal of maintaining broad-based equity participation, delivering value that is aligned with our compensation philosophy and proactively managing our share usage as well as dilution during a period of rapid growth.
Results of Fiscal 2019 Stockholder Advisory Vote
At our 2020 Annual Meeting of Stockholders, we conducted our first non-binding stockholder advisory vote on the compensation of our named executive officers for 2018, which consist(commonly known as a “Say-on-Pay” vote). Our stockholders approved our Say-on-Pay proposal with approximately 67.1% of the votes cast in favor of the fiscal 2019 compensation of our principalnamed executive officers. While this represented support for our executive compensation program, our Board of Directors has continued to benchmark, against peers, our governance practices and executive compensation program. After taking into the account the results of the 2020 Say-on-Pay vote and other considerations, we have made the following changes to our governance practices and compensation program:
•Adopted director and executive officer stock ownership guidelines;
•Amended our equity incentive plans to provide that equity awards granted thereunder are generally subject to minimum vesting of at least one year and to prohibit cash buyouts of options and option repricings without the next two most highly compensated executive officers, are:Peter Maag, Ph.D.,consent of our Chief Executive Officer;
stockholders;Reginald Seeto, MBBS, our President and Chief Business Officer; and
•Adopted a compensation recovery (“clawback”) policy;Michael Bell, our Chief Financial Officer.
Processes and Procedures for Compensation Decisions
30
•Our Compensation Committee is responsible for the executive compensation programscash bonus program for our executive officers for 2021 includes both financial and reports to our Board of Directors on its discussions, decisionsnon-financial metrics; and other actions.
•The salary and bonuses paidPRSUs granted to our executive officers in 2021 are reviewed annuallybased on a two-year performance period with one year of additional vesting (if performance criteria are achieved, 50% will vest at the end of the two-year performance period and the remaining 50% will vest the following year).
II.Compensation Philosophy
We operate within a very complex business environment, which requires a very strong management team. Our business model requires our management team to be adept at developing competitive technologies to support multiple customers, including hospitals, all within multiple geographies. Many of our competitors have substantially greater capital resources and larger sales forces than we do. In addition, the diagnostics industry is characterized by rapid product development and technological advances, which require our management team to be adept at managing these key areas of the business.
As a result, the Compensation Committee believes that it is critical to attract, develop and retain a highly-qualified management team with the experience, knowledge, expertise and vision capable of not only operating, but also excelling, in this complex and competitive business environment, including competing against larger competitors and developing and commercializing new products, new and improved technologies and new applications for our existing technologies.
Our executive compensation program is intended to help us achieve and foster a goal-oriented, highly-motivated management team with a clear understanding of our business objectives and shared corporate values. To this end, the Compensation Committee believes that our executive compensation program should provide compensation that:
•attracts and retains the best executive talent;
•appropriately aligns our business objectives and stockholder interests;
•maintains a reasonable balance across types and purposes of compensation;
•motivates our executive officers to achieve our annual and long-term strategic goals and rewards performance based on the attainment of such goals;
•appropriately considers risk and reward in the context of our business environment and long-range business plans;
•recognizes individual value and contributions to our success; and
•considers, but does not exclusively rely upon, competitive market data.
We seek to achieve these objectives in a way that is consistent with the long-term interests of our company and those of our stakeholders, including our stockholders and employees. We structure the annual compensation of our executive officers, including our NEOs, using three principal elements: base salary, annual and equity cash incentives and long-term compensation opportunities in the form of equity awards.
Our Compensation Committee believes that our compensation program should align executive interests with the drivers of growth and stockholder returns, and support achievement of our primary business goals. The expertise, leadership and contributions of our executives are critical to our ability to create sustained long-term stockholder value. Consequently, our board believes the substantial majority of NEO compensation should be at-risk, variable pay to facilitate the successful execution of our business strategy.
III.Compensation Determination Process
Role of Compensation Committee
The Compensation Committee discharges the responsibilities of our Board relating to the compensation of our executive officers. The Compensation Committee consists of directors who are “independent” directors as required by the Nasdaq listing standards and Securities Exchange Act of 1934, as amended (“Exchange Act”), Rule 10C-1, and “non-employee directors” for purposes of Exchange Act Rule 16b-3.
The Compensation Committee. Typically,Committee has responsibility for overseeing our compensation and benefits policies generally, and overseeing, evaluating and approving the compensation plans, policies and programs applicable to our CEO, as well as our other executive officers, including our other NEOs. In carrying out its responsibilities, the Compensation Committee evaluates our compensation policies and practices with a focus on the degree to which these policies and practices reflect our executive compensation philosophy, develops recommendations, makes decisions that it believes advances our philosophy and reviews the performance of our executive officers when making decisions with respect to their compensation.
The Compensation Committee conducts reviews of the Company’s compensation policies and programs on at least an annual basis to ensure that they enhance stockholder value, align pay and performance, and attract and retain top executive talent. This includes a review of internal pay equity among the executive team. With the assistance of our independent compensation consultant, the Compensation Committee seeks to maintain appropriate base salary, annual bonus and equity compensation plans for its executives.
Role of CEO, Executive Chair & Management
Our Chief Executive Officer,
in consultation with our Executive Chair, makes recommendations to our Compensation Committee, often attends committee meetings and is involved in the determination of compensation for the respective executive officers who report to him, except that the Chief Executive Officer does not make recommendations as to his own compensation.
The compensation of our Executive Chair is set by our Compensation Committee, and our Chief Executive Officer is not involved in such determination. Our Chief Executive Officer,
in consultation with our Executive Chair, makes recommendations to our Compensation Committee regarding short- and long-term compensation for all executive officers (other than himself) based on our results, an individual executive officer’s contribution toward these results and performance toward individual goal achievement.
OurEach of our Chief Executive Officer
and our Executive Chair recuses himself from Compensation Committee and board discussions when his compensation is reviewed. Our Compensation Committee then reviews the recommendations and other data and makes decisions as to total compensation for each executive officer other than the Chief Executive Officer
and our Executive Chair, as well as each individual compensation component. Our Compensation Committee makes recommendations to our Board of Directors regarding, or determines, compensation for the Chief Executive
Officer.Officer and our Executive Chair. The Compensation Committee or the independent members of our Board of Directors make the final decisions regarding executive compensation for the Chief Executive
Officer.Officer and the Executive Chair. The Compensation Committee does not delegate any of its functions to others in deciding executive compensation.
Use of Independent Compensation Consultant
Our Compensation Committee is authorized to retain the services of one or more executive compensation advisors, as it sees fit, in connection with the establishment of our compensation programs and related policies. BeginningThe Compensation Committee has retained Radford, part of the Rewards Solutions practice at Aon plc, as its independent outside compensation consultant since 2014 to assist with setting executive compensation. The Compensation Committee has sole authority to retain or replace such independent compensation consultants. The Compensation Committee annually evaluates the compensation consultant’s independence and performance under the applicable Nasdaq listing standards. The Compensation Committee believes that working with an independent compensation consultant furthers the Company’s objectives to recruit and retain qualified executives, align executive interests with those of stockholders and ensure that executive compensation packages will appropriately motivate and reward ongoing achievement of business goals.
In 2020, Radford provided the following services to the Compensation Committee:
•Reviewed and recommended adjustments to the Company’s peer group;
•Conducted an extensive executive compensation assessment; and
•Provided key insights on executive and director compensation based on relevant market data.
Radford did not provide any services to us other than the consulting services to the Compensation Committee. The Compensation Committee conducted a review of its relationship with Radford in 2014,2020 and determined that Radford’s work for the Compensation Committee retaineddid not raise any conflicts of interest. The Compensation Committee determined that Radford’s work has conformed to the independence factors and guidance provided by the SEC and the Nasdaq.
Use of a Peer Group
With the assistance and recommendations of Radford, Associates,the Compensation Committee has developed a national compensation consultant,peer group of companies as a reference group to provide information, recommendationsa broad perspective on competitive pay levels and other advice about executive compensation on an ongoing basis. Accordingly, Radford now serves atpractices.
In December 2019, the discretion of our Compensation Committee. Our Compensation Committee engaged Radfordapproved a peer group for use in making 2020 compensation decisions. When selecting appropriate peers, the general criteria used were:
•Industry - Public diagnostics companies
•Revenues- Between $25 million - $300 million
•Market Capitalization- between $300 million and $3 billion
For compensation decisions for fiscal year 2020, the following public companies were selected as our peer group:
2020 Peer Group
| | | | | | | | | | | |
| Cerus Corporation | Fluidigm Corporation | GenMark Diagnostics, Inc. | Invitae Corporation |
| iRhythm Technologies | Luminex Corporation | Meridian Bioscience, Inc. | Myriad Genetics, Inc. |
| Nanostring Technologies, Inc. | Natera, Inc. | NeoGenomics, Inc. | OraSure Technologies, Inc. |
| Oxford Immunotec Global PLC | Quanterix Corporation | Quidel Corporation | Veracyte, Inc. |
The Compensation Committee does not engage in formal benchmarking against other companies’ compensation programs or practices to assistestablish our compensation levels or make specific compensation decisions with respect to our executive officers, including our NEOs. Instead, in developing an appropriatemaking its determinations, the Compensation Committee reviews information summarizing the compensation paid at a representative group of peer companies, to help us determine the appropriate levelextent that the executive positions at these companies are considered comparable to our positions and informative of overall compensation for our executive officers,the competitive environment, as well as assess each separate elementmore broad-based compensation surveys to gain a general understanding of market compensation with a goallevels.
Assessment of ensuring thatRisk
The Compensation Committee also considers the compensation we offer topotential risks in our business when designing and administering our executive officers is competitivecompensation program, and fair.we believe our balanced approach to performance measurement and pay delivery works to avoid misaligned incentives for individuals to undertake excessive or inappropriate risk.
Summary Compensation Table
The following table provides information regarding the
IV.Pay Components
Our executive compensation
awarded to, or earned by, our named executive officers during 2017program consists of three primary elements: base salaries, annual cash incentives, and
2018.Summary Compensation Table
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Name and Principal Position(1) | | Year | | | Salary
($) | | | Stock
Awards
($)(2) | | | Option
Awards
($)(3) | | | Non-Equity
Incentive Plan
Compensation
($)(4) | | | All Other
Compensation
($) | | | Total ($) | |
| Peter Maag, Ph.D., | | | 2018 | | | | 483,750 | | | | 2,728,322 | | | | 1,324,759 | | | | 693,000 | | | | 1,560 | | | | 5,231,391 | |
| Chief Executive Officer | | | 2017 | | | | 450,000 | | | | 306,900 | | | | 264,837 | | | | 378,000 | | | | 1,560 | | | | 1,401,297 | |
Reginald Seeto, MBBS | | | 2018 | | | | 40,909 | | | | 1,386,000 | | | | 1,711,391 | | | | 30,000 | | | | 80 | | | | 3,168,380 | |
| President and Chief Business Officer | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Michael Bell | | | 2018 | | | | 340,653 | | | | 1,006,422 | | | | 438,090 | | | | 308,284 | | | | 1,560 | | | | 2,095,009 | |
| Chief Financial Officer | | | 2017 | | | | 237,292 | | | | 147,500 | | | | 190,544 | | | | 114,319 | | | | 1,105 | | | | 690,760 | |
(1) | In accordance
| | | | | | | | | | | | | | | | | | | |
| Element | | Performance
Period | | Objective | | Performance Measured / Rewarded |
| Base Salary | | Annual | | Attracts, retains, and rewards top talent and reflects an NEO’s responsibilities, performance, and relevant market data | | •Provides NEOs with SEC guidance,fixed compensation informationthat acts as a vehicle to motivate and retain. Rewards executives for Reginald Seeto, MBBSkey performance and contributions |
| Annual Incentives | | Annual | | Rewards achievement of annual company goals subject to meeting individual performance expectations | | •Rewards NEOs for their individual performance and the performance of the Company over the fiscal year 2017 has not been included2020 incentives, which include cash bonuses and equity in this table because Reginald Seeto, MBBS was notthe form of performance-based RSUs (“PRSUs”) are based on the Company’s financial and strategic goals. The three metrics used for 2020 were: ◦Total Sales - 50% weighting ◦AlloSure Volume - 25% weighting ◦Adjusted EBITDA - 25% weighting |
| Long-Term Incentives | | Long-Term (four years) | | Aligns the interests of management and stockholders and serves as an important retention vehicle Supports the achievement of strong share price growth | | •NEOs receive a mix of time-based RSUs and time-based stock options to reward long term stock price growth and encourage employee retention. |
CareDx is committed to a strong performance orientation in our compensation program and effective corporate governance practices for a company at our development stage and industry. As such we routinely review our policies and program design. Some of our best practices in governance that we observe include:
| | | | | |
| What We Do | |
☑ Pay-for-performance alignment—commencing with 2021, our annual cash bonus program includes both financial and non-financial metrics, and our PRSUs have a two-year performance period with one year of additional vesting thereafter ☑ Maintain an Insider Trading Policy ☑ Align compensation with stockholder interests ☑ Maintain “Double Trigger” benefits in the case of a Change in Control ☑ Annual compensation review ☑ Recommending annual stockholder advisory vote on named executive officer compensation ☑ Provide only very limited perquisites to executives | ☑ Director and executive officer stock ownership guidelines ☑ Balanced pay mix of fixed and variable pay ☑ Multi-year vesting requirements for fiscalstock options and certain restricted stock unit awards ☑ Robust anti-hedging and pledging policies ☑ Retain an independent compensation consultant ☑ Only independent directors serve on our board committees ☑ Compensation recovery (“clawback”) policy ☑ Provide that equity awards granted under our equity incentive plans are subject to minimum vesting of at least one year 2017. |
(2)What We Don’t Do | The amounts in this column represent the fair value of the award computed as of the grant date of each stock award computed in accordance with FASB ASC Topic 718. Our assumptions with respect to the calculation of these values are set forth in Note 14 of the consolidated financial statements included in our Annual Report on Form
10-K
for the year ended December 31, 2018.
|
(3)☒ Provide excessive severance payments ☒ Use excise tax gross-ups ☒ Utilize guaranteed bonuses ☒ Provide single trigger change-in-control severance payments ☒ Provide excessive perquisites ☒ Provide special executive retirement plans | The amounts in this column represent the aggregate fair value of the award computed as of the grant date of each option award in accordance with FASB ASC Topic 718. Our assumptions with respect to the calculation of these values are set forth in Note 14 of the consolidated financial statements included in our Annual Report on Form
10-K☒ for the year ended December 31, 2018.
|
(4) | Represents amounts paid as a discretionary bonus Provide special welfare benefits to our executive officers including our named executive officers, for their performance in 2018 as compared against
☒ Permit the performance goals set in our Executive Incentive Compensation Plan.payment of dividends on RSUs or PRSUs prior to vesting ☒ Permit cash buyouts of options without stockholder consent ☒ Permit option repricings without stockholder consent |
Non-Equity Incentive Plan Compensation
Each
Base Salary
Base salary is the only fixed component of our named executive officers is eligible forofficers’ total cash annual incentive payments. For 2018, Dr. Maag hadcompensation and provides competitive pay to attract and retain our executives. Generally, we use base salary to provide each executive officer with a target annual incentivespecified level of upcash compensation during the year with the expectation that he or she will perform his or her responsibilities to 70%the best of his or her ability and in our best interests. Annual salary decisions are made in recognition of competitive data as well as the skills and experience that each individual brings to the Company and the performance contributions each makes.
Base salary changes in 2020 varied by executive due either to merit increases and/or market adjustments. The increases in 2020 were based on a review of market data from Radford for similar roles and positions within our compensation peer group and an assessment of the following factors:
•Peer group data and external market information;
•Individual performance;
•The level of responsibility assumed and the nature and complexity of each NEO’s role;
•The leadership demonstrated to create and promote a day-to-day working environment; and
•The desire to attract, engage and retain NEOs capable of achieving the Company’s strategic objectives and the marketability and criticality of retention of NEOs.
Annual base salaries for our NEOs as of December 31, 2019 and December 31, 2020* were as follows:
| | | | | | | | | | | | | | | | | | | | | | | |
| Named Executive Officer | | 2019 | | 2020 | | | Increase |
| Peter Maag, Ph.D. | | $ | 514,800 | | | $ | 270,000 | | (1) | | N/A |
| Reginald Seeto, MBBS | | 400,000 | | | 540,000 | | (2) | | 35.0 | % |
Sasha King(3) | | 290,400 | | | 310,000 | | | | 6.7 | % |
Michael Bell(4) | | 359,700 | | | 430,000 | | (5) | | 19.5 | % |
Marcel Konrad(6) | | 279,600 | | | 287,970 | | | | 3.0 | % |
*See footnotes for a description of the changes to base salary and Mr. Bell was eligible for a target annual incentivethat were effected throughout 2020. Actual amounts of 45% of his base salary.Payment of an incentive is based on our performance against certain key performance indicators. For 2018, our key performance indicators included Total Sales, AlloSure Volume and EBITDA. We measure our actual performance against our budgeted goals, and then determine an incentive payout. For fiscal year 2018, our executive officers were awarded between 180% and 200% of the target annual bonus amounts, andsalary paid to our NEOs were specifically awardedare described in the following percentages of their target annual bonus amounts:
“Summary Compensation Table” below. Employment Agreements for Named Executive Officers
Peter Maag, Ph.D.
We entered into a Chief Executive Employment Agreement with Dr. Maag, dated September 19, 2012, under which Dr. Maag serves as our Chief Executive Officer. The agreement provides for“at-will”(1) employment and
sets forth certain agreed upon terms and conditions of employment. During fiscal year 2018,Effective April 1, 2020, Dr. Maag’s annual base salary was $450,000, which was increased to $495,000 effective$540,000. Upon Dr. Maag’s transition from Chief Executive Officer to Executive Chairman on November 1, 2020, Dr. Maag’s annual base salary was decreased to $270,000.
(2)Effective April 1, 2018 and which was further increased to $514,800 effective April 1, 2019. He is currently eligible for a target annual bonus of up to 80% of his base salary.Reginald Seeto, MBBS
We entered into an offer letter with Dr. Seeto, dated November 16, 2018, under which Dr. Seeto serves as our President and Chief Business Officer. The agreement provides for“at-will” employment and sets forth certain agreed upon terms and conditions of employment. During fiscal year 2018,2020, Dr. Seeto’s annual base salary was $400,000. He is currently eligible for a targetincreased to $410,000. Effective upon Dr. Seeto’s transition from Chief Business Officer to Chief Executive Officer on November 1, 2020, Dr. Seeto’s annual bonus of upbase salary was increased to 70% of$540,000, which was Dr. Maag’s salary as Chief Executive Officer immediately prior to his transition to Executive Chairman.
(3)Effective April 1, 2020, Ms. King’s annual base salary.Michael Bell
We entered into an offer letter with salary was increased to $310,000.
(4)Mr. Bell datedresigned effective December 31, 2020.
(5)Effective April 21, 2017, under which Mr. Bell serves as our Chief Financial Officer. The agreement provides for“at-will” employment and sets forth certain agreed upon terms and conditions of employment. During fiscal year 2018,1, 2020, Mr. Bell’s annual base salary was $335,000, whichincreased to $380,000. Effective November 1, 2020, Mr. Bell’s salary was increased to $342,538$430,000.
(6)Mr. Konrad was appointed as our Interim Chief Financial Officer effective April 1, 2018December 31, 2020 and which was further increasedserved in this role until March 25, 2021.
Annual Incentives
Our cash bonus program is designed to $359,700 effective April 1, 2019. He is currently eligibleprovide a financial incentive to reward key executives for the achievement of annual corporate performance objectives. Under the cash bonus program, each NEO has an award opportunity expressed as a target annual bonus of up to 60%percentage of his or her base salary.Potential Payments under the program and Benefits upon Terminationvesting of the performance restricted stock unit awards (“
PRSUs”) are ultimately based on the achievement of pre-established Company metrics. Actual performance against these metrics determines the Company factor for purposes of calculating payments under the cash bonus program (the “Company Factor”) and determines the level of vesting of the PRSUs. Threshold levels of performance must be met for bonuses to be earned and vesting to occur. For purposes of our cash bonus program, in 2020, the Company Factor could range from zero to 200%. For 2020, the cash bonus program and the PRSUs granted to our executive officers used three metrics for funding and vesting purposes: Total Sales, AlloSure Volume (number of AlloSure tests performed) and Adjusted EBITDA. We define Adjusted EBITDA as non-GAAP net income/(loss) before net interest expense, income tax expense, depreciation and amortization, other expense, and net loss attributable to noncontrolling interest.
For each of these three metrics, in the first quarter of 2020, the Compensation Committee established performance thresholds at the following levels: less than 25% achievement; 25% achievement; 50% achievement; 100% achievement; 150% achievement; and 200% or Changegreater achievement. The Compensation Committee set the Company Factor at 177% based on the Company’s 2020 achievements.
Once the Company Factor is determined based on Company performance against the metrics above, a modifier is applied based on individual performance. Our Compensation Committee has discretion to grant individual cash bonus awards at, below, or above target based on individual performance and the funding available in the bonus pool. Final awards under the program are subject to adjustment, positively or negatively, for individual performance against key Company objectives. Individual performance is assessed against various objectives falling into five categories: Patients; Performance; Partnering; Pipeline; and People, as well as additional criteria related to competencies and included targeted numbers of Controlpatient results, recruitment of patients and centers, partnering and acquisitions, product and service launches and employee recruitment matters. Depending on each individual’s score, the final bonus amount is adjusted in a range of 75% to 120%. Therefore, through our cash bonus program, NEOs may earn a significantly higher payout if target performance is exceeded. NEOs also bear the risk of a lower payout if target performance is not achieved, and the risk of no payout for below-threshold results.
To arrive at each Named Executive Officer’s earned bonus for 2020, the Compensation Committee multiplied the Named Executive Officer’s base salary, by the Named Executive Officer’s annual target bonus percentage, by the Company Factor (177%), by the Named Executive Officer’s individual performance factor, as determined by the Compensation Committee.
The cash bonuses paid to our Named Executive Officers
Peter Maag, Ph.D.
Pursuant for 2020 were:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Named Executive Officer* | | Base Salary
for Purposes of Bonus | | | 2020 Annual Target Bonus (% of base) | | Company Factor | | Individual Performance Multiplier | | 2020 Earned Bonus |
| Peter Maag, Ph.D. | | $ | 540,000 | | (1) | | 90 | % | (1) | | 1.77 | | | 1.0 | (2) | | $ | 860,220 | |
| Reginald Seeto, MBBS | | $ | 410,000 | | (3) | | 70 | % | (2) | | 1.77 | | | 1.1 | | | $ | 558,789 | |
| Sasha King, M.B.A. | | $ | 310,000 | | | | 60 | % | | | 1.77 | | | 1.1 | | | $ | 362,142 | |
Marcel Konrad, M.B.A.(4) | | $ | 287,970 | | | | 25 | % | | | 1.77 | | | 1.2 | | | $ | 152,913 | |
---------------------
*No bonus was paid to Mr. Bell as he resigned on December 31, 2020.
(1)Although Dr. Maag’s Change of Controlbase salary was decreased from $540,000 to $270,000 and Severance Agreement, dated May 1, 2014, if within two monthshis target bonus was increased from 90% to 100% in connection with Dr. Maag’s transition from Chief Executive Officer to Executive Chairman, Dr. Maag’s 2020 bonus was calculated based on his base salary and target bonus prior to or twelve months following a change of control, we or our successor terminateNovember 1, 2020, as reflected in this table.
(2)Although Dr. Maag’s employment without cause,individual performance multiplier was determined to be 1.2, his bonus was capped at 177% of his target bonus amount.
(3)Although Dr. MaagSeeto’s base salary was increased from $410,000 to $540,000 and his target bonus was increased from 70% to 90% in connection with Dr. Seeto’s transition from Chief Business Officer to Chief Executive Officer, Dr. Seeto’s 2020 bonus was calculated based on his base salary and target bonus prior to November 1, 2020, as reflected in this table.
(4)Mr. Konrad was appointed as our Interim Chief Financial Officer effective December 31, 2020 and served in this role until March 25, 2021.
Awards under our cash bonus program are typically paid in the quarter following the close of the performance period. For 2021, our cash bonus program metrics include both financial and non-financial metrics, including those related to our pipeline.
Long-Term Incentives
Our focus on long-term value creation results in our executive compensation program having a heavy weighting toward equity compensation, which includes stock options and restricted stock units (RSUs). We rely heavily on equity compensation that vests over a multi-year period to ensure that a significant portion of a named executive officer’s compensation opportunity is related to factors that directly and indirectly influence stockholder value. Our Compensation Committee believes this serves as a reward for appreciation in our stock price and long-term value creation, and enables us to achieve our retention objectives. Further, equity participation establishes a sense of ownership and aligns executives’ interests with those of our other stockholders.
In 2020, we provided a significant portion of our executives’ target long-term incentives via a mix of stock options and RSUs. Approximately 40% of the value of our equity awards granted in 2020 was in the form of long-term stock options (four year vesting period), 30% of the value was in the form of long-term RSUs (four year vesting period) and 30% of the value was in the form of annual PRSUs, or a total of 70% of the value comprised of long-term incentives. The Compensation Committee believes this structure is appropriate for us given our current competitive recruiting landscape, our current company size and our current growth trajectory.
For 2021, the PRSUs granted to our executive officers in 2021 are long-term incentives and will have a two-year performance period with one year of additional vesting (if performance criteria are achieved, 50% will vest at the end of the two-year performance period and the remaining 50% will vest the following year).
2020 Annual Equity Grants
A summary our regular, annual cycle grants for 2020, which were granted on February 3, 2020, is as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Named Executive Officer(1) | | PRSUs
(Granted/Vested) | | RSUs | | Stock Options |
| (#) | | ($)(2) | | (#) | | ($)(3) | | (#) | | ($)(4) |
| Peter Maag, Ph.D. | | 40,000 | | | $ | 974,000 | | | 40,000 | | | $ | 974,000 | | | 80,000 | | | $ | 1,266,803 | |
| Reginald Seeto, MBBS | | 20,000 | | | $ | 487,000 | | | 20,000 | | | $ | 487,000 | | | 40,000 | | | $ | 633,402 | |
| Sasha King, M.B.A | | 8,000 | | | $ | 194,800 | | | 8,000 | | | $ | 194,800 | | | 16,000 | | | $ | 253,361 | |
Michael Bell(5) | | 15,000 | | | $ | 365,250 | | | 15,000 | | | $ | 365,250 | | | 30,000 | | | $ | 475,051 | |
(1)Mr. Konrad was appointed as the Company’s Interim Chief Financial Officer effective December 31, 2020 and was not an executive officer at the time these grants were made and he is therefore not included in this table.
(2)The PRSUs were granted on February 3, 2020. Amounts set forth in this column generally represent the aggregate grant date fair value of the PRSU awards granted to each listed NEO, computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718 (“ASC Topic 718”). These amounts do not represent the actual amounts paid to or realized by the NEOs.
(3)The RSUs were granted on February 3, 2020. Amounts set forth in this column generally represent the aggregate grant date fair value of the RSU awards granted to each listed NEO, computed in accordance with ASC Topic 718. These amounts do not represent the actual amounts paid to or realized by the NEOs.
(4)The stock options were granted on February 3, 2020. Amounts set forth in this column reflect the grant date fair value of the option awards, computed in accordance with ASC Topic 718. All of these amounts reflect certain assumptions with respect to the option awards and do not necessarily correspond to the actual value that will be entitledrecognized by our NEOs. The actual value, if any, that may be realized from an option award is contingent upon the satisfaction of the conditions to (a) twelve months’ severance, (b) accelerationvesting of vesting equal to 100%that award, and upon the excess of the stock price over the exercise price, if any, unvested options, (c) a lump sum payment equal to Dr. Maag’s annual bonus, and (d) twelve months of continued benefits,provided, that such reimbursement will cease on the date the option award is exercised. See Note 14 of the Notes to Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 that Dr. Maag becomes covered underwas filed with the SEC on February 24, 2021 for a similar plandiscussion of a new employer. Pursuantthe assumptions made in determining the grant date fair value of the stock options.
(5)None of the PRSUs, RSUs or options granted to Mr. Bell as reflected in this table vested as he resigned effective December 31, 2020.
PRSUs
In early February 2020, our Compensation Committee granted PRSUs to our executive officers. The PSRUs are sized to reflect one-half of the full value awards given to each executive, other than Mr. Konrad, who was not an executive officer in February 2020.
The PRSUs are designed to further reward key executives for the achievement of corporate performance objectives. The vesting of the PRSUs was based on the achievement of the same pre-established Company metrics used for purposes of determining the Company Factor for the Company’s 2020 cash bonus program, as discussed above. For each of these three metrics, for purposes of the PRSUs, the Compensation Committee established performance thresholds at the following levels: less than 25% achievement; 25% achievement; 50% achievement; 100% or greater achievement.
Vesting of the PRSUs granted in 2020 was determined in the first quarter of 2021. The Compensation Committee determined to vest 100% of the shares of common stock subject to the agreement, if2020 PRSUs based on determining the Company Factor at above 100%.
RSUs - Vesting
The foregoing RSU grants vest over four years in equal annual installments on the anniversary of the date of grant, beginning at the first anniversary of the date of grant.
Stock Options - Vesting
One quarter of the foregoing option grants vest at the first anniversary of the date of grant. The balance of the option grants vest monthly over a three-year period, subject to continuing service on each vesting date.
2020 Additional Equity Grants
In addition to our regular, annual equity awards, in July 2020, we made awards of additional RSUs and options to our NEOs. These awards were made in order to recognize that in prior years the number of shares available for grant under our equity plan was not adequate to allow for the size of grant the Compensation Committee would have ideally made in light of factors such as performance and common equity grant practices among peers.
A summary of these additional RSU and option grants for 2020 is as follows:
| | | | | | | | | | | | | | | | | | | | | | | |
Named Executive Officer(1) | RSUs | | Options |
| (#) | | ($)(2) | | (#) | | ($)(3) |
| Peter Maag, Ph.D. | 40,000 | | $ | 1,379,600 | | | 20,000 | | $ | 455,132 | |
| Reginald Seeto, MBBS | 40,000 | | $ | 1,379,600 | | | 20,000 | | $ | 455,132 | |
Michael Bell(4) | 40,000 | | $ | 1,379,600 | | | 20,000 | | $ | 455,132 | |
| Sasha King | 5,000 | | $ | 172,450 | | | 2,500 | | $ | 56,891 | |
(1)Mr. Konrad was appointed as the Company’s Interim Chief Financial Officer effective December 31, 2020 and was not an executive officer at the time these grants were made and he is therefore not included in this table.
(2)The RSUs were granted on July 6, 2020. The dollar amounts generally represent the aggregate grant date fair value of the RSU awards granted to each listed NEO, computed in accordance with ASC Topic 718. The dollar amounts do not represent the actual amounts paid to or a successor terminate Dr. Maag’s employment without causerealized by the NEOs.
(3)The stock options were granted on July 6, 2020. Amounts set forth in this column reflect the grant date fair value of the option awards, computed in accordance with ASC Topic 718. All of these amounts reflect certain assumptions with respect to the option awards and such termination occurs outside of a change of control event, Dr. Maagdo not necessarily correspond to the actual value that will be entitledrecognized by our NEOs. The actual value, if any, that may be realized from an option award is contingent upon the satisfaction of the conditions to (a) twelve months’ severance,vesting of that award, and (b) twelve monthsupon the excess of continued benefits,provided, that such reimbursement will ceasethe stock price over the exercise price, if any, on the date the option award is exercised. See Note 14 of the Notes to Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 that was filed with the SEC on February 24, 2021 for a discussion of the assumptions made in determining the grant date fair value of the stock options.
(4)None of the RSUs or options granted to Mr. Bell as reflected in this table vested as he resigned effective December 31, 2020.
The additional RSUs granted in July 2020 vest over four years in equal annual installments on the anniversary of the date of grant, beginning at the first anniversary of the date of grant.
One quarter of the additional option grants vest at the first anniversary of the date of grant. The balance of the option grants vest monthly over a three-year period, subject to continuing service on each vesting date.
2020 Equity Grants in Connection with Dr. Maag becomes coveredSeeto’s Promotion to Chief Executive Officer
In connection with Dr. Seeto’s promotion to the Company’s Chief Executive Officer, on November 2, 2020, Dr. Seeto was granted an option to purchase 19,000 shares of the Company’s common stock, 6,100 RSUs and 6,100 PRSUs under
a similar plan of a new employer.Reginald Seeto, MBBS
Pursuantthe Company’s 2014 Plan. The option will vest, subject to Dr. Seeto’s Changecontinued employment with the Company, 1/4th on November 2, 2021, and 1/48th of Control and Severance Agreement, datedthe total number of shares subject to the option will vest at the end of each calendar month thereafter. The RSUs will vest at a rate of 25% per year on each one-year anniversary from November 26, 2018, if within two months prior2, 2020. The PRSUs will vest upon the achievement of certain pre-established milestones relating to total sales. A summary of these awards is as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
PRSUs
(Granted/Vested) | | RSUs | | Stock Option |
| (#) | | ($)(1) | | (#) | | ($)(2) | | (#) | | ($)(3) |
| 6,100 | | | $ | 292,556 | | | 6,100 | | $ | 292,556 | | | 19,000 | | $ | 602,417 | |
(1)The PRSUs were granted on November 2, 2020. Amount set forth in this column generally represents the aggregate grant date fair value of the PRSU award granted to Dr. Seeto, computed in accordance with ASC Topic 718. This amount does not represent the actual amounts paid to or twelve months following a changerealized by Dr. Seeto.
(2)The RSUs were granted on November 2, 2020. Amount set forth in this column generally represents the aggregate grant date fair value of control, we or our successor terminate Dr. Seeto’s employment without cause,the RSU award granted to Dr. Seeto, computed in accordance with ASC Topic 718. This amount does not represent the actual amounts paid to or realized by Dr. Seeto.
(3)The stock option was granted on November 2, 2020. Amounts set forth in this column reflect the grant date fair value of the option awards, computed in accordance with ASC Topic 718. All of these amounts reflect certain assumptions with respect to the option
awards and do not necessarily correspond to the actual value that will be entitledrecognized by Dr. Seeto. The actual value, if any, that may be realized from an option award is contingent upon the satisfaction of the conditions to (a) six months’ severance, (b) accelerationvesting of vesting equal to 100%that award, and upon the excess of the stock price over the exercise price, if any, unvested options, (c) a lump sum payment equal to Dr. Seeto’s annual bonus and (d) six months of continued benefits, provided, that such reimbursement will cease on the date the option award is exercised. See Note 14 of the Notes to Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 that Dr. Seeto becomes coveredwas filed with the SEC on February 24, 2021 for a discussion of the assumptions made in determining the grant date fair value of the stock options.
2020 Equity Grants in Connection with Mr. Konrad’s Appointment as our Interim Chief Financial Officer
In connection with Mr. Konrad’s appointment as the Company’s Interim Chief Financial Officer, on December 10, 2020, Mr. Konrad was granted 4,000 RSUs under a similar planthe Company’s 2014 Plan. All of a new employer. Pursuantthe shares subject to the agreement, if we or a successor terminate Dr. Seeto’sRSUs will vest on December 10, 2021, subject to Mr. Konrad’s continued employment without causewith the Company. Mr. Konrad was appointed as our Interim Chief Financial Officer effective December 31, 2020 and such termination occurs outside of a change of control event, Dr. Seeto will be entitled to (a) six months’ severance,served in this role until March 25, 2021.
Welfare and (b) six months of continued benefits,provided, that such reimbursement will ceaseHealth Benefits
Our NEOs participate in our employee benefit plans on the
date that Dr. Seeto becomes covered under a similar plan of a new employer.Michael Bell
Pursuant to Mr. Bell’s Change of Control and Severance Agreement, dated April 17, 2017, if within two months prior to, or twelve months following a change of control, we or our successor terminate Mr. Bell’s employment
without cause, Mr. Bell will be entitled to (a) twelve months’ severance, (b) acceleration of vesting equal to 100% of any unvested options, (c) a lump sum payment equal to Mr. Bell’s annual bonus and (d) twelve months of continued benefits, provided, that such reimbursement will cease on the date that Mr. Bell becomes covered under a similar plan of a new employer. Pursuant to the agreement, if we or a successor terminate Mr. Bell’s employment without cause and such termination occurs outside of a change of control event, Mr. Bell will be entitled to (a) six months’ severance, and (b) six months of continued benefits,provided, that such reimbursement will cease on the date that Mr. Bell becomes covered under a similar plan of a new employer.
For purposes of the change of control agreements, “cause” means generally:
executive’s material failure to perform his stated duties after a notice of failure and a cure period of ten days;
executive’s material violation of our policies or any written agreement or covenant with us;
executive’s conviction of, or entry of a plea of guilty or nolo contendere to, a felony;
a willful act by executive that constitutes gross misconduct and which is injurious to us;
executive’s commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct that has caused or is reasonably expected to result in material injury to us;
the unauthorized use or disclosure by executive of any of our proprietary information or trade secrets or any other party to whom he owes an obligation of nondisclosuresame terms as a result of his relationship with us; or
executive’s willful failure to cooperate with an investigation by a governmental authority.
401(k) Plan
Our retirement plan, which we refer to as the 401(k) plan, is qualified under Section 401 of the Code. Eligible employees, including all of our full-time employees, may elect to reduce their current compensation by an amount no greater than the statutorily prescribed annual limit and may have that amount contributed to theother eligible employees.
We maintain a tax-qualified Code Section 401(k) plan. Matching contributions may be made to the 401(k)defined contribution plan at the discretionin which all of our Boardemployees, including our executive officers, who satisfy certain eligibility requirements, including requirements relating to age and length of Directors.service, are entitled to participate. Employees may contribute their own funds on a pre-tax basis.
The plan permits us to make matching contributions and we have historically provided employer contributions that match eligible employee contributions (“employer matching contributions”), generally limited to 3% of the compensation (up to a maximum matching contribution of $5,000 per year) that can be taken into account for this purpose under federal law. On January 1, 2018, we began to make contributions to the 401(k)employee plan. We matched 50 cents on the dollarEmployer matching contributions vest according to a four-year graded plan at a rate of the first four percent25% per year.
In addition, we provide health care, dental, vision and life insurance, an employee contributesassistance plan and both short-term and long-term disability and accidental death and dismemberment benefits to all full-time employees. These benefits are subject to applicable laws and at benefit levels that we believe are generally consistent with the 401(k) plan (maximum capbenefits of $4,000). Beginning on January 1, 2019,companies with which we changedcompete for talent.
Limited Perquisites
In 2020, the contributionCompany provided certain limited perquisites to dollar for dollar on the first three percent an employee contributesour NEOs, which related to the 401(k) plan (with a cap of $5,000).
Outstanding Equity Awards at FiscalYear-End
The following table presents certain information concerning equity awards held by our executive officers, including each of our named executive officers, as of December 31, 2018.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | Option Awards | | | Stock Awards | |
Name | | Grant Date | | | Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable | | | Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable | | | Option
Exercise
Price ($) | | | Option
Expiration
Date | | | Number of
Shares or
Units of
Stock
That Have
Not
Vested (#) | | | Market
Value of
Shares of
Stock
That Have
Not
Vested ($) | |
Peter Maag, Ph.D. | | | 3/6/2015 | (1) | | | 40,697 | | | | 1,667 | | | | 6.49 | | | | 3/6/2025 | | | | — | | | | — | |
| | | 1/22/2016 | (2) | | | 46,484 | | | | 17,266 | | | | 5.27 | | | | 1/22/2026 | | | | — | | | | — | |
| | | 2/17/2017 | (3) | | | 28,750 | | | | 31,250 | | | | 2.30 | | | | 2/17/2027 | | | | — | | | | — | |
| | | 9/1/2017 | (4) | | | 13,542 | | | | 11,458 | | | | 2.80 | | | | 9/1/2027 | | | | — | | | | — | |
| | | 10/27/2017 | (5) | | | 13,125 | | | | 31,875 | | | | 5.90 | | | | 10/27/2027 | | | | — | | | | — | |
| | | 11/09/2017 | (6) | | | 23,158 | | | | 23,158 | | | | 5.49 | | | | 11/9/2024 | | | | — | | | | — | |
| | | 1/19/2018 | (7) | | | | | | | 44,425 | | | | 6.31 | | | | 1/19/2028 | | | | — | | | | — | |
| | | 6/29/2018 | (8) | | | — | | | | 150,000 | | | | 12.24 | | | | 6/29/2028 | | | | — | | | | — | |
| | | 3/6/2015 | (9) | | | — | | | | — | | | | — | | | | — | | | | 6,250 | | | | 157,125 | |
| | | 1/22/2016 | (10) | | | — | | | | — | | | | — | | | | — | | | | 10,625 | | | | 267,113 | |
| | | 2/17/2017 | (11) | | | — | | | | — | | | | — | | | | — | | | | 13,500 | | | | 339,390 | |
| | | 10/27/2017 | (12) | | | — | | | | — | | | | — | | | | — | | | | 45,000 | | | | 1,131,300 | |
| | | 1/19/2018 | (13) | | | — | | | | — | | | | — | | | | — | | | | 44,425 | | | | 1,116,845 | |
| | | 6/29/2018 | (14) | | | — | | | | — | | | | — | | | | — | | | | 150,000 | | | | 3,771,000 | |
Michael Bell | | | 4/21/2017 | (15) | | | 4,167 | | | | 23,333 | | | | 1.00 | | | | 4/21/2027 | | | | — | | | | — | |
| | | 9/1/2017 | (4) | | | 5,417 | | | | 4,583 | | | | 2.80 | | | | 9/1/2027 | | | | — | | | | — | |
| | | 10/27/2017 | (5) | | | 13,125 | | | | 31,875 | | | | 5.90 | | | | 10/27/2027 | | | | — | | | | — | |
| | | 1/19/2018 | (7) | | | — | | | | 14,013 | | | | 6.31 | | | | 1/19/2028 | | | | — | | | | — | |
| | | 6/29/2018 | (8) | | | — | | | | 50,000 | | | | 12.24 | | | | 6/29/2028 | | | | — | | | | — | |
| | | 10/27/2017 | (12) | | | — | | | | — | | | | — | | | | — | | | | 25,000 | | | | 628,500 | |
| | | 1/19/2018 | (16) | | | | | | | — | | | | — | | | | — | | | | 14,013 | | | | 352,287 | |
| | | 6/29/2018 | (17) | | | — | | | | — | | | | — | | | | — | | | | 50,000 | | | | 1,257,000 | |
Reginald Seeto, MBBS | | | 11/26/2018 | (18) | | | | | | | 100,000 | | | | 27.72 | | | | 11/26/2028 | | | | — | | | | — | |
| | | 11/26/2018 | (19) | | | — | | | | — | | | | — | | | | — | | | | 50,000 | | | | 1,257,000 | |
(1) | One quarter of the total shares vested on January 21, 2016, and 1/48th of the shares subject to the option vested and will vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.
|
(2) | One quarter of the total shares vested on January 22, 2017, and 1/48th of the shares subject to the option vested and will vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.
|
(3) | One quarter of the total shares vested on January 27, 2018, and 1/48th of the shares subject to the option vested and will vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.
|
(4) | One half of the total shares vested on September 1, 2018 and 1/72nd of the shares subject to the option will vest monthly thereafter.
|
(5) | One quarter of the total shares vested on October 20, 2018 and 1/48th of the shares subject to the option will vest monthly thereafter.
|
(6) | Options are scheduled to vest in three equal installments based upon the Company’s achievement of certain performance goals as follows: (i) one third of the options vest upon the Company’s determination, which has been reviewed by the Company’s independent registered public accounting firm, that the Company has achieved $10 million of total cumulative sales of AlloSure, its proprietary next-generation sequencing-based
|
| test to detect donor-derived, cell-free DNA after transplantation, commencing November 8, 2017, (ii) one third of the options vest upon the Company’s determination, which has been reviewed by the Company’s independent registered public accounting firm, that the Company has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after November 8, 2017, and (iii) one third of the options vest in the event the closing sales price of the Company’s common stock is at or above $5.00 per share, as quoted by Nasdaq, for 10 consecutive trading days after November 8, 2017. |
(7) | Full grant amount is unvested as of December 31, 2018. One quarter of the total shares vest on January 19, 2019 and 1/48th of the shares subject to the option vest each month thereafter.
|
(8) | Full grant amount is unvested as of December 31, 2018. One quarter of the total shares vest on June 1, 2019 and 1/48th of the shares subject to the option vest each month thereafter.
|
(9) | 6,250 of the shares subject to this RSU award vested on January 21, 2018. An additional 6,250 of the shares subject to this RSU award vested on January 21, 2019.
|
(10) | 5,313 of the shares subject to this RSU award vested on January 21, 2018. An additional 5,313 of the shares subject to this RSU award vested on January 21, 2019, and 5,313 of the shares will vest on January 21, 2020.
|
(11) | 4,500 of the shares subject to this RSU award vested on January 27, 2018. An additional 4,500 of the shares subject to this RSU award vested on January 27, 2019 and 4500 of the shares will vest on each of January 27, 2020 and January 27, 2021.
|
(12) | Full grant amount is unvested as of December 31, 2018. The shares subject to this RSU vested in full on March 1, 2019, upon such time that the Company’s independent registered public accounting firm determined, pursuant to a review or audit of the Company’s financial information or statements, that the Company achieved more than $60.0 million in revenue in 2018.
|
(13) | Full grant amount is unvested as of December 31, 2018. 11,106 of the shares subject to this RSU award vested on January 19, 2019. An additional 11,106 of the shares subject to this RSU award will vest on each of January 19, 2020, January 19, 2021 and January 19, 2022.
|
(14) | Full grant amount is unvested as of December 31, 2018. 37,500 of the shares subject to this RSU award will vest on June 1, 2019. An additional 37,500 of the shares subject to this RSU award will vest on each of June 1, 2020, June 1, 2021 and June 1, 2022.
|
(15) | One quarter of the total shares vested on April 17, 2018, and 1/48th of the shares subject to the option will vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.
|
(16) | Full grant amount is unvested as of December 31, 2018. One quarter of the shares subject to this RSU award vested on January 19, 2019. An additional one quarter of the shares subject to this RSU award will vest on each of January 19, 2020, January 19, 2021 and January 19, 2022.
|
(17) | Full grant amount is unvested as of December 31, 2018. 12,500 of the shares subject to this RSU award will vest on June 1, 2019. An additional 12,500 of the shares subject to this RSU award will vest on each of June 1, 2020, June 1, 2021 and June 1, 2022.
|
(18) | Full grant amount is unvested as of December 31, 2018. One quarter of the total shares vest on November 26, 2019 and 1/48th of the shares subject to the option vest each month thereafter.
|
(19) | Full grant amount is unvested as of December 31, 2018. 12,500 of the shares subject to this RSU award will vest on November 26, 2019. An additional 12,500 of the shares subject to this RSU award will vest on each of November 26, 2020, November 26, 2021 and November 26, 2022.
|
RSUelectronic allowances and Performance Unit Deferral Election Program
In December 2018, the Compensation Committee approved an RSU and performance unit deferral election program, pursuant to which ournon-employee directors, executive officers and certain other employees may elect, on an annual basis, to defer the settlement of all RSU and performance unit awards granted to such individuals in the following fiscal year, so that such awards will settle in a number of substantially equal annual installments selected by the individual, on every June 30 starting in the calendar year immediately following the year in which the individual incurs a separation of service.
gym allowances.Hedging and Pledging Policies
Prohibitions
Our insider trading policy prohibits our directors, officers (including our executive officers), employees and agents, as well as their immediate family members, from engaging in short sales of our securities and from engaging in transactions in publicly-traded options and other derivative securities with respect to our securities. This prohibition extends to any hedging or similar transactions designed to decrease the risks associated with holding our securities. Our insider trading policy also prohibits certain individuals, including our directors and executive officers, from pledging our securities as collateral for loans.
Employment Agreement and Offer Letter Summaries
We have entered into employment agreements or offer letters with each of the named executive officers. These agreements provide for at-will employment and generally include the named executive officer’s initial base salary, and an indication of eligibility for an annual cash incentive award opportunity.
Peter Maag, Ph.D.
We entered into a Chief Executive Employment Agreement with Dr. Maag, dated September 19, 2012, under which Dr. Maag previously served as our Chief Executive Officer. The agreement provided for “at-will” employment and sets forth certain agreed upon terms and conditions of employment. During fiscal year 2020, Dr. Maag’s annual base salary was $514,800, which was increased to $540,000 effective April 1, 2020. In 2020, he was eligible for a target annual performance bonus of up to 90% of his base salary.
In connection with Dr. Maag’s appointment as the Company’s Executive Chair effective November 1, 2020, the Company and Dr. Maag entered into an Executive Chair Agreement. The Executive Chair Agreement superseded Dr. Maag’s prior Chief Executive Employment Agreement and provides that Dr. Maag’s annual base salary is $270,000 and that he is eligible for a target annual performance bonus of 100% of his annual base salary. In addition, any time-based vesting equity awards that Dr. Maag held as of the date of the Executive Chair Agreement or that are thereafter granted to Dr. Maag will automatically vest through June 30, 2024 if Dr. Maag’s employment with the Company is terminated by the Company without cause (as defined in the Executive Chair Agreement) before June 30, 2024.
Reginald Seeto, MBBS
We entered into an offer letter with Dr. Seeto, dated November 16, 2018, under which Dr. Seeto initially served as our President and Chief Business Officer. The agreement provides for “at-will” employment and sets forth certain agreed upon terms and conditions of employment. During fiscal year 2020, Dr. Seeto’s annual base salary was $400,000, which was increased to $410,000 effective April 1, 2020. In 2020, Dr. Seeto was eligible for a target annual performance bonus of up to 70% of his base salary. In connection with Dr. Seeto’s appointment as the Company’s Chief Executive Officer, effective as of November 1, 2020, the Compensation Committee approved an increase in Dr. Seeto’s base salary to $540,000 and an increase in his target annual performance bonus to a 90% of his annual base salary.
Sasha King
We entered into an offer letter with Ms. King, dated October 20, 2017, under which Ms. King initially served as our Chief Commercial Officer. The agreement provides for “at-will” employment and sets forth certain agreed upon terms and conditions of employment. On June 16, 2019, Ms. King transitioned from Chief Commercial Officer to our Chief Marketing Officer to better align with her focus and contributions to the Company. During fiscal year 2020, Ms. King’s annual base salary was $290,400, which was increased to $310,000 effective April 1, 2020. In 2020, she was eligible for a target annual performance bonus of up to 60% of her base salary.
Michael Bell
We entered into an offer letter with Mr. Bell, dated April 21, 2017, under which Mr. Bell serves as our Chief Financial Officer. The agreement provides for “at-will” employment and sets forth certain agreed upon terms and conditions of employment. During fiscal year 2020, Mr. Bell’s annual base salary was $359,700, which was increased to $380,000 effective April 1, 2020 and further increased to $430,000 effective November 1, 2020. Prior to his resignation in 2020, he was eligible for a target annual performance bonus of up to 60% of his base salary. Mr. Bell resigned from the Company effective December 31, 2020.
Marcel Konrad
We entered into an offer letter with Mr. Konrad, dated August 20, 2018, under which Mr. Konrad initially served as our Vice President, Corporate Controller. The agreement provides for “at-will” employment and sets forth certain agreed upon terms and conditions of employment. Effective December 31, 2020, Mr. Konrad was appointed our Interim Chief Financial Officer. During fiscal year 2020, Mr. Konrad’s annual base salary was $287,970. In 2020, he was eligible for a target annual performance bonus of up to 25% of his base salary. Mr. Konrad was appointed as our Interim Chief Financial Officer effective December 31, 2020 and served in this role until March 25, 2021.
Potential Payments and Benefits upon Termination or Change of Control for Officers
Peter Maag, Ph.D.
Pursuant to Dr. Maag’s Change of Control and Severance Agreement, if within two months prior to, or twelve months following a change of control, we or our successor terminate Dr. Maag’s employment without cause, Dr. Maag will be entitled to (a) twelve months’ severance based on Dr. Maag’s annual base salary, (b) acceleration of vesting equal to 100% of any unvested equity awards, (c) a lump sum payment equal to Dr. Maag’s annual bonus (equal to the greater of target bonus or the actual bonus received for performance during the calendar year prior to the year in which the termination occurs) , and (d) twelve months of continued benefits, provided, that such reimbursement will cease on the date that Dr. Maag becomes covered under a similar plan of a new employer. Pursuant to the agreement, if we or a successor terminate Dr. Maag’s employment without cause and such termination occurs outside of a change of control event, Dr. Maag will be entitled to (a) twelve months’ severance based on Dr. Maag’s annual base salary, and (b) twelve months of continued benefits, provided, that such reimbursement will cease on the date that Dr. Maag becomes covered under a similar plan of a new employer. Additionally,
pursuant to the Executive Chair Agreement, if we terminate Dr. Maag’s employment with the Company without cause prior to June 30, 2024, such portion of each of Dr. Maag’s equity awards as would have vested on or through June 30, 2024 shall automatically be deemed vested as of such termination of employment; provided, that for purposes of the foregoing, any equity awards subject to the achievement of performance criteria shall not be accelerated vesting unless otherwise determined by the Board of Directors (or its Compensation Committee) in its sole and absolute discretion with respect to any unvested portion thereof that would have otherwise vested through and including June 30, 2024.
Reginald Seeto, MBBS
Pursuant to Dr. Seeto’s Change of Control and Severance Agreement, dated November 26, 2018, as amended by the Amendment to Change of Control and Severance Agreement, dated October 29, 2020, if within two months prior to, or twelve months following a change of control, we or our successor terminate Dr. Seeto’s employment without cause, Dr. Seeto will be entitled to (a) twelve months’ severance based on Dr. Seeto’s annual base salary, (b) acceleration of vesting equal to 100% of any unvested equity awards, (c) a lump sum payment equal to Dr. Seeto’s annual bonus (equal to the greater of target bonus or the actual bonus received for performance during the calendar year prior to the year in which the termination occurs) and (d) twelve months of continued benefits, provided, that such reimbursement will cease on the date that Dr. Seeto becomes covered under a similar plan of a new employer. Pursuant to the agreement, if we or a successor terminate Dr. Seeto’s employment without cause and such termination occurs outside of a change of control event, Dr. Seeto will be entitled to (a) twelve months’ severance based on Dr. Seeto’s annual base salary, and (b) twelve months of continued benefits, provided, that such reimbursement will cease on the date that Dr. Seeto becomes covered under a similar plan of a new employer.
Michael Bell
Pursuant to Mr. Bell’s Change of Control and Severance Agreement, dated April 17, 2017, if within two months prior to, or twelve months following a change of control, we or our successor terminated Mr. Bell’s employment without cause, Mr. Bell would have been entitled to (a) twelve months’ severance based on Mr. Bell’s annual base salary, (b) acceleration of vesting equal to 100% of any unvested equity awards, (c) a lump sum payment equal to Mr. Bell’s annual bonus (equal to the greater of target bonus or the actual bonus received for performance during the calendar year prior to the year in which the termination occurred) and (d) twelve months of continued benefits, provided, that such reimbursement would cease on the date that Mr. Bell became covered under a similar plan of a new employer. Pursuant to the agreement, if we or a successor terminated Mr. Bell’s employment without cause and such termination occurred outside of a change of control event, Mr. Bell would have been entitled to (a) six months’ severance based on Mr. Bell’s annual base salary, and (b) six months of continued benefits, provided, that such reimbursement would cease on the date that Mr. Bell became covered under a similar plan of a new employer.
Sasha King
Pursuant to Ms. King’s Change of Control and Severance Agreement, dated October 20, 2017, if within two months prior to, or twelve months following a change of control, we or our successor terminate Ms. King’s employment without cause, Ms. King will be entitled to (a) twelve months’ severance based on Ms. King’s annual base salary, (b) acceleration of vesting equal to 100% of any unvested equity awards, (c) a lump sum payment equal to Ms. King’s annual bonus (equal to the greater of target bonus or the actual bonus received for performance during the calendar year prior to the year in which the termination occurs) and (d) twelve months of continued benefits, provided, that such reimbursement will cease on the date that Ms. King becomes covered under a similar plan of a new employer. Pursuant to the agreement, if we or a successor terminate Ms. King’s employment without cause and such termination occurs outside of a change of control event, Ms. King will be entitled to (a) six months’ severance based on Ms. King’s annual base salary, and (b) six months of continued benefits, provided, that such reimbursement will cease on the date that Ms. King becomes covered under a similar plan of a new employer.
Marcel Konrad
During 2020, we did not have any agreement with Mr. Konrad providing for benefits in the event of a change of control.
For purposes of the Change of Control and Severance Agreements with Drs. Maag and Seeto, Mr. Bell and Ms. King, “cause” means generally:
•executive’s material failure to perform his or her stated duties after a notice of failure and a cure period of ten days;
•executive’s material violation of our policies or any written agreement or covenant with us;
•executive’s conviction of, or entry of a plea of guilty or nolo contendere to, a felony;
•a willful act by executive that constitutes gross misconduct and which is injurious to us;
•executive’s commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct that has caused or is reasonably expected to result in material injury to us;
•the unauthorized use or disclosure by executive of any of our proprietary information or trade secrets or any other party to whom he or she owes an obligation of nondisclosure as a result of his or her relationship with us; or
•executive’s willful failure to cooperate with an investigation by a governmental authority.
The following table estimates the amounts payable to our named executive officers that were serving as such as of the end of December 31, 2020 in the event that a change of control, termination of employment or both occurred on December 31, 2020. The closing price of our common stock on December 31, 2020, as reported on the Nasdaq Global Market, was $72.45 per share. The following tables exclude certain benefits, such as accrued vacation, that are available to all employees generally. The actual amount of payments and benefits that would be provided can only be determined at the time of a change of control and/or the named executive officer’s qualifying separation from the Company:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Termination by the Company without Cause Outside of Change of Control Window | | Termination by the Company Without Cause During Change of Control Window |
Name(1) | | Cash Payments | | Continuation of Benefits | | Cash Payments | | Continuation of Benefits | | Value of Equity Accelerated |
| Peter Maag, Ph.D. | | $ | 270,000 | | | $ | 25,234 | | | $ | 838,339 | | | $ | 25,234 | | | $33,371,168 (2) |
| Reginald Seeto, MBBS | | $ | 540,000 | | | $ | 26,350 | | | $ | 1,026,000 | | | $ | 26,350 | | | $ | 14,809,347 | |
| Sasha King | | $ | 155,000 | | | $ | 6,250 | | | $ | 526,406 | | | $ | 12,499 | | | $ | 8,886,653 | |
(1) Excludes Michael Bell as he resigned effective December 31, 2020. Also excludes Mr. Konrad as we did not have any agreement with Mr. Konrad providing for benefits in the event of a change of control during 2020.
(2) Assumes the Board of Directors (or its Compensation Committee) would determine to accelerate the vesting of equity awards subject to the achievement of performance criteria and that the performance criteria were achieved at target level.
Accounting and Tax Considerations
The Company accounts for equity-based compensation paid to employees under FASB ASC Topic 718, which requires the Company to estimate and record an expense over the service period of an option award. Thus, the Company may record an expense in one year for awards granted in earlier years. Accounting rules also require the recording of cash compensation as an expense at the time the obligation is accrued.
Section 162(m) of the Internal Revenue Code of 1986, as amended, generally disallows public companies a tax deduction for federal income tax purposes of compensation in excess of $1 million paid to their chief executive officer, the chief financial officer and three other most highly-compensated executive officers in any taxable year. In making compensation decisions, the Compensation Committee considered the potential effects of Section 162(m) on the compensation paid our executive officers who are subject to the deduction limit (the “covered executives”). The exemption from Section 162(m)’s deduction limit for performance-based compensation was generally repealed for taxable years beginning after December 31, 2017, such that compensation paid to our covered officers in excess of $1 million will generally not be deductible unless it qualifies for transition relief applicable to certain arrangements in place as of November 2, 2017.
To maintain flexibility in compensating the NEOs in a manner designed to promote varying corporate goals, the Compensation Committee has not adopted a policy that all compensation payable to the covered executives must be deductible for federal income tax purposes. Accordingly, while the Compensation Committee considers the deductibility of awards as one factor in determining executive compensation, the Compensation Committee also looks at other factors in making its decisions and retains the flexibility to award compensation that it determines to be consistent with the goals of our executive compensation program even if the awards are not deductible by us for tax purposes.
In addition to considering the tax consequences, the Compensation Committee considers the accounting consequences of its decisions, including the impact of expenses being recognized in connection with equity-based awards, in determining the size and form of different equity-based awards.
Compensation Committee Report on Executive Compensation
The Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K of the SEC’s rules and regulations with management and, based on such review and discussions, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this proxy statement.
The Compensation Committee:
Fred E. Cohen, M.D., D. Phil
Grace E. Colón, Ph.D.
Michael D. Goldberg
William A. Hagstrom
Summary Compensation Table
The following table provides information regarding the compensation awarded to, or earned by, our named executive officers during 2018, 2019 and 2020.
Summary Compensation Table
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Name and
Principal Position | | Year | | Salary
($) | | Stock Awards ($)(1) | | Option Awards ($)(2) | | Non-Equity Incentive Plan Compensation ($)(3) | | All Other Compensation
($) | | Total ($) |
Peter Maag, Ph.D., Executive Chair and Former Chief Executive Officer | | 2020 | | 488,700 | | | 3,327,600 | | | 1,721,935 | | | 860,220 | | | 1,560 | | | 6,400,015 | |
| 2019 | | 510,030 | | | 6,673,480 | | | 1,670,674 | | | 568,339 | | | 1,560 | | | 9,424,083 | |
| 2018 | | 483,750 | | | 2,728,322 | | | 1,324,759 | | | 693,000 | | | 1,560 | | | 5,231,391 | |
| Michael Bell | | 2020 | | 383,249 | | | 2,110,100 | | | 930,183 | | | — | | | 20,420 | | | 3,443,952 | |
Former Chief Financial Officer(4) | | 2019 | | 355,383 | | | 1,442,210 | | | 556,891 | | | 327,582 | | | 3,621 | | | 2,685,687 | |
| 2018 | | 340,653 | | | 1,006,422 | | | 438,090 | | | 308,284 | | | 1,560 | | | 2,095,009 | |
Reginald Seeto, MBBS Chief Executive Officer, President and Chief Business Officer | | 2020 | | 429,167 | | | 2,938,712 | | | 1,690,950 | | | 558,789 | | | 1,080 | | | 5,618,698 | |
| 2019 | | 400,000 | | | 572,770 | | | 556,891 | | | 425,040 | | | 960 | | | 1,955,661 | |
| 2018 | | 40,909 | | | 1,386,000 | | | 1,711,391 | | | 30,000 | | | 80 | | | 3,168,380 | |
Sasha King, M.B.A.(5) Chief Marketing Officer | | 2020 | | 305,100 | | | 562,050 | | | 310,252 | | | 362,142 | | | 1,560 | | | 1,541,104 | |
| 2019 | | 283,800 | | | 721,105 | | | 278,446 | | | 216,406 | | | 8,993 | | | 1,508,750 | |
Marcel Konrad, M.B.A. (6) Former Interim Chief Financial Officer | | 2020 | | 283,659 | | | 409,570 | | 106,367 | | 152,913 | | 960 | | 953,469 |
(1)The amounts in this column represent the fair value of the award computed as of the grant date of each stock award computed in accordance with FASB ASC Topic 718. Our assumptions with respect to the calculation of these values are set forth in Note 14 of the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 that was filed with the SEC on February 24, 2021.
(2)The amounts in this column represent the aggregate fair value of the award computed as of the grant date of each option award in accordance with FASB ASC Topic 718. Our assumptions with respect to the calculation of these values are set forth in Note 14 of the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 that was filed with the SEC on February 24, 2021.
(3)Represents amounts paid as a discretionary bonus to our executive officers, including our named executive officers, for their performance in 2020 as compared against the performance goals set in our Executive Incentive Compensation Plan.
(4)Mr. Bell resigned effective December 31, 2020.
(5)In accordance with SEC guidance, compensation information for Sasha King for fiscal year 2018 has not been included in this table because Sasha King was not a named executive officer for fiscal year 2018.
Grants of Plan-Based Awards
The following table presents, for each of the named executive officers, information concerning each grant of an equity award made during the fiscal year ended December 31, 2020. This information supplements the information about these awards set forth in the Summary Compensation Table and the Outstanding Equity Awards at Fiscal Year-End Table.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Estimated Future Payouts
Under
Equity Incentive Plan Awards | | All Other Stock Awards: Number of shares of stock or units (#) | | All Other Option Awards: Number of Securities Underlying Options (#) | | Exercise Price Per Share
($) | | Grant Date Fair Value of Stock and Option Awards ($)(1) |
| Name | | Grant
Date | | Threshold
(#) | | Target
(#) | | Maximum
(#) | | | | |
| Peter Maag, Ph.D. | | 2/3/2020(2) | | | | | | | | 40,000 | | | — | | | — | | | 974,000 | |
| | 2/3/2020(3) | | 2,500 | | | 40,000 | | | 40,000 | | | — | | | — | | | — | | | 974,000 | |
| | 2/3/2020(4) | | | | | | | | — | | | 80,000 | | | 24.35 | | | 1,266,803 | |
| | 7/6/2020(2) | | | | | | | | 40,000 | | | — | | | — | | | 1,379,600 | |
| | 7/6/2020(4) | | | | | | | | — | | | 20,000 | | | 34.49 | | | 455,132 | |
Michael Bell(5) | | 2/3/2020(2) | | | | | | | | 15,000 | | | — | | | — | | | 365,250 | |
| | 2/3/2020(3) | | 938 | | | 15,000 | | | 15,000 | | | — | | | — | | | — | | | 365,250 | |
| | 2/3/2020(4) | | | | | | | | — | | | 30,000 | | | 24.35 | | | 475,051 | |
| | 7/6/2020(2) | | | | | | | | 40,000 | | | — | | | — | | | 1,379,600 | |
| | 7/6/2020(4) | | | | | | | | | | 20,000 | | | 34.49 | | | 455,132 | |
| Reginald Seeto, MBBS | | 2/3/2020(2) | | | | | | | | 20,000 | | | — | | | — | | | 487,000 | |
| | 2/3/2020(3) | | 1,250 | | | 20,000 | | | 20,000 | | | — | | | — | | | — | | | 487,000 | |
| | 2/3/2020(4) | | | | | | | | — | | | 40,000 | | | 24.35 | | | 633,402 | |
| | 7/6/2020(2) | | | | | | | | 40,000 | | | — | | | — | | | 1,379,600 | |
| | 7/6/2020(4) | | | | | | | | — | | | 20,000 | | | 34.49 | | | 455,132 | |
| | 11/2/2020(2) | | | | | | | | 6,100 | | | — | | | — | | | 292,556 | |
| | 11/2/2020(6) | | 381 | | | 6,100 | | | 6,100 | | | — | | | — | | | — | | | 292,556 | |
| | 11/2/2020(4) | | | | | | | | — | | | 19,000 | | | 47.96 | | | 602,417 | |
| Sasha King | | 2/3/2020(2) | | | | | | | | 8,000 | | | — | | | — | | | 194,800 | |
| | 2/3/2020(3) | | 500 | | | 8,000 | | | 8,000 | | | — | | | — | | | — | | | 194,800 | |
| | 2/3/2020(4) | | | | | | | | — | | | 16,000 | | | 24.35 | | | 253,361 | |
| | 7/6/2020(2) | | | | | | | | 5,000 | | | — | | | — | | | 172,450 | |
| | 7/6/2020(4) | | | | | | | | — | | | 2,500 | | | 34.49 | | | 56,891 | |
Marcel Konrad(7) | | 4/20/2020(2) | | | | | | | | 4,000 | | | — | | | — | | | 92,400 | |
| | 4/20/2020(4) | | | | | | | | — | | | 4,000 | | | 23.10 | | | 60,853 | |
| | 7/6/2020(2) | | | | | | | | 1,000 | | | — | | | — | | | 34,490 | |
| | 7/6/2020(4) | | | | | | | | — | | | 2,000 | | | 34.49 | | | 45,513 | |
| | 12/10/2020(8) | | | | | | | | 4,000 | | | — | | | — | | | 282,680 | |
(1)Amounts reflect the aggregate grant date fair value of the RSUs and stock option awards, determined in accordance with ASC 718. This amount does not reflect the actual economic value realized by the named executive officer.
(2)Vesting of the RSU is subject to the executive’s continued employment on the applicable vesting date with the following schedule: 25% of the total number of shares vesting on the one-year anniversary of the grant date, with 25% vesting on each successive grant date anniversary.
(3)Represents a grant of a performance restricted stock unit (“PRSU”), which provided that it would vest upon the achievement of certain milestones relating to total sales, AlloSure volume and Adjusted EBITDA. Grant date fair value reflects the target (and maximum) number of shares subject to the PRSU award, assuming all performance goals and other requirements are met.
(4)Vesting of the option is subject to the executive’s continued employment on the applicable vesting date with the following schedule: 25% of the total number of shares vesting on the one-year anniversary of the grant date, with 1/48th vesting monthly thereafter.
(5)Mr. Bell resigned effective December 31, 2020.
(6)Represents a grant of a PRSU, which provided that it would vest upon the achievement of certain milestones relating to total sales. Grant date fair value reflects the target (and maximum) number of shares subject to the PRSU award, assuming all performance goals and other requirements are met.
(7)Mr. Konrad was appointed as our Interim Chief Financial Officer effective December 31, 2020 and served in this role until March 25, 2021.
(8)All shares subject to the RSU shall vest on the one-year anniversary of the grant date.
Outstanding Equity Awards at Fiscal Year-End
The following table presents certain information concerning equity awards held by our named executive officers as of December 31, 2020.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Option Awards | | Stock Awards |
| Name* | | Grant Date | | Number of Securities Underlying Unexercised Options (#) Exercisable | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | Option Exercise Price ($) | | Option Expiration Date | | Number of Shares or Units of Stock That Have Not Vested (#) | | Market Value of Shares of Stock That Have Not Vested ($) |
| Peter Maag, Ph.D. | | 1/22/2016(1) | | 13,281 | | | — | | | 5.27 | | | 1/22/2026 | | — | | | — | |
| | 2/17/2017(2) | | 15,000 | | | 1,250 | | | 2.30 | | | 2/17/2027 | | — | | | — | |
| | 9/1/2017(3) | | 4,167 | | | 3,125 | | | 2.80 | | | 9/1/2027 | | — | | | — | |
| | 10/27/2017(4) | | 11,250 | | | 9,375 | | | 5.90 | | | 10/27/2027 | | — | | | — | |
| | 1/19/2018(5) | | 18,108 | | | 12,032 | | | 6.31 | | | 1/19/2028 | | — | | | — | |
| | 6/29/2018(6) | | 93,750 | | | 56,250 | | | 12.24 | | | 6/29/2028 | | — | | | — | |
| | 2/4/2019(7) | | 46,000 | | | 50,000 | | | 27.17 | | | 2/4/2029 | | — | | | — | |
| | 2/3/2020(8) | | — | | | 80,000 | | | 24.35 | | | 2/3/2030 | | — | | | — | |
| | 7/6/2020(9) | | — | | | 20,000 | | | 34.49 | | | 7/6/2030 | | — | | | — | |
| | 2/17/2017(10) | | — | | | — | | | — | | | — | | | 4,500 | | | 10,350 | |
| | 1/19/2018(11) | | — | | | — | | | — | | | — | | | 22,212 | | | 140,158 | |
| | 6/29/2018(12) | | — | | | — | | | — | | | — | | | 75,000 | | | 918,000 | |
| | 2/4/2019(13) | | — | | | — | | | — | | | — | | | 36,000 | | | 978,120 | |
| | 8/6/2019(14) | | — | | | — | | | — | | | — | | | 37,500 | | | 1,035,375 | |
| | 2/3/2020(15) | | — | | | — | | | — | | | — | | | 40,000 | | | 974,000 | |
| | 2/3/2020(16) | | — | | | — | | | — | | | — | | | 40,000 | | | 974,000 | |
| | 7/6/2020(17) | | — | | | — | | | — | | | — | | | 40,000 | | | 1,379,600 | |
| Michael Bell | | 4/21/2017(18) | | 3,334 | | | 3,333 | | | 1.00 | | | 4/21/2027 | | — | | | — | |
| | 9/1/2017(18) | | 417 | | | 1,250 | | | 2.80 | | | 9/1/2027 | | — | | | — | |
| | 10/27/2017(18) | | 3,750 | | | 9,375 | | | 5.90 | | | 10/27/2027 | | — | | | — | |
| | 1/19/2018(18) | | 1,168 | | | 3,795 | | | 6.31 | | | 1/19/2028 | | — | | | — | |
| | 6/29/2018(18) | | 3,125 | | | 18,750 | | | 12.24 | | | 6/29/2028 | | — | | | — | |
| | 2/4/2019(18) | | 2,666 | | | 16,667 | | | 27.17 | | | 2/4/2029 | | — | | | — | |
| | 2/3/2020(18) | | — | | | 30,000 | | | 24.35 | | | 2/3/2030 | | — | | | — | |
| | 7/6/2020(18) | | — | | | 20,000 | | | 34.49 | | | 7/6/2030 | | — | | | — | |
| | 1/19/2018(19) | | — | | | — | | | — | | | — | | | 7,006 | | | 44,208 | |
| | 6/29/2018(19) | | — | | | — | | | — | | | — | | | 25,000 | | | 306,000 | |
| | 2/4/2019(19) | | — | | | — | | | — | | | — | | | 12,000 | | | 326,040 | |
| | 8/6/2019(19) | | — | | | — | | | — | | | — | | | 3,750 | | | 103,538 | |
| | 2/3/2020(19) | | — | | | — | | | — | | | — | | | 15,000 | | | 365,250 | |
| | 2/3/2020(20) | | — | | | — | | | — | | | — | | | 15,000 | | | 365,250 | |
| | 7/6/2020(19) | | — | | | — | | | — | | | — | | | 40,000 | | | 1,379,600 | |
| Reginald Seeto, | | 11/26/2018(21) | | 52,083 | | | 47,917 | | | 27.72 | | | 11/26/2028 | | — | | | — | |
| MBBS | | 2/4/2019(7) | | 15,333 | | | 16,667 | | | 27.17 | | | 2/4/2029 | | — | | | — | |
| | 2/3/2020(8) | | — | | | 40,000 | | | 24.35 | | | 2/3/2030 | | — | | | — | |
| | 7/6/2020(9) | | — | | | 20,000 | | | 34.49 | | | 7/6/2030 | | — | | | — | |
| | 11/2/2020(22) | | — | | | 19,000 | | | 47.96 | | | 11/2/2030 | | — | | | — | |
| | 11/26/2018(23) | | — | | | — | | | — | | | — | | | 25,000 | | | 693,000 | |
| | 8/6/2019(24) | | — | | | — | | | — | | | — | | | 3,750 | | | 103,538 | |
| | 2/3/2020(25) | | — | | | — | | | — | | | — | | | 20,000 | | | 487,000 | |
| | 2/3/2020(26) | | — | | | — | | | — | | | — | | | 20,000 | | | 487,000 | |
| | 7/6/2020(16) | | — | | | — | | | — | | | — | | | 40,000 | | | 1,379,600 | |
| | 11/2/2020(27) | | — | | | — | | | — | | | — | | | 6,100 | | | 292,556 | |
| | 11/2/2020(28) | | — | | | — | | | — | | | — | | | 6,100 | | | 292,556 | |
| Sasha King | | 4/21/2017(29) | | 750 | | | 750 | | | 1.00 | | | 4/21/2027 | | — | | | — | |
| | 6/9/2017(30) | | 625 | | | 1,250 | | | 1.07 | | | 6/9/2027 | | — | | | — | |
| | 9/1/2017(3) | | 278 | | | 1,250 | | | 2.80 | | | 9/1/2027 | | — | | | — | |
| | 10/27/2017(4) | | 2,500 | | | 8,333 | | | 5.90 | | | 10/27/2027 | | — | | | — | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 1/19/2018(5) | | 1,250 | | | 5,417 | | | 6.31 | | | 1/19/2028 | | — | | | — | |
| | 6/29/2018(6) | | 2,083 | | | 18,750 | | | 12.24 | | | 6/29/2028 | | — | | | — | |
| | 2/4/2019(7) | | 1,000 | | | 8,333 | | | 27.17 | | | 2/4/2029 | | — | | | — | |
| | 2/3/2020(8) | | — | | | 16,000 | | | 24.35 | | | 2/3/2030 | | — | | | — | |
| | 7/6/2020(9) | | — | | | 2,500 | | | 34.49 | | | 7/6/2030 | | — | | | — | |
| | 6/29/2018(31) | | — | | | — | | | — | | | — | | | 25,000 | | | 306,000 | |
| | 2/4/2019(32) | | — | | | — | | | — | | | — | | | 6,000 | | | 163,020 | |
| | 8/6/2019(33) | | — | | | — | | | — | | | — | | | 1,875 | | | 51,769 | |
| | 2/3/2020(34) | | — | | | — | | | — | | | — | | | 8,000 | | | 194,800 | |
| | 2/3/2020(35) | | — | | | — | | | — | | | — | | | 8,000 | | | 194,800 | |
| | 7/6/2020(36) | | — | | | — | | | — | | | — | | | 2,500 | | | 172,450 | |
| Marcel Konrad | | 9/10/2018(37) | | 1,917 | | | 8,333 | | | 26.96 | | | 9/10/2028 | | — | | | — | |
| | 4/18/2019(38) | | 584 | | | 2,333 | | | 26.50 | | | 4/18/2029 | | — | | | — | |
| | 4/20/2020(39) | | — | | | 4,000 | | | 23.10 | | | 4/20/2030 | | — | | | — | |
| | 7/6/2020(40) | | — | | | 2,000 | | | 34.49 | | | 7/6/2030 | | — | | | — | |
| | 9/10/2018(41) | | — | | | — | | | — | | | — | | | 2,650 | | | 71,444 | |
| | 4/18/2019(42) | | — | | | — | | | — | | | — | | | 1,500 | | | 39,750 | |
| | 4/20/2020(43) | | — | | | — | | | — | | | — | | | 4,000 | | | 92,400 | |
| | 7/6/2020(44) | | — | | | — | | | — | | | — | | | 1,000 | | | 34,490 | |
| | 12/10/2020(45) | | — | | | — | | | — | | | — | | | 4,000 | | | 282,680 | |
(1)One quarter of the total shares vested on January 22, 2017, and 1/48th of the shares subject to the option vested each month thereafter, subject to executive’s continued employment on each applicable vesting date.
(2)One quarter of the total shares vested on January 27, 2018, and 1/48th of the shares subject to the option vested and will vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.
(3)One half of the total shares vested on September 1, 2018 and 1/72nd of the shares subject to the option vested and will vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.
(4)One quarter of the total shares vested on October 20, 2018 and 1/48th of the shares subject to the option vested and will vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.
(5)One quarter of the total shares vested on January 19, 2019 and 1/48th of the shares subject to the option vested and will vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.
(6)One quarter of the total shares vested on June 1, 2019 and 1/48th of the shares subject to the option vested and will vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.
(7)One quarter of the total shares vested on February 4, 2019 and 1/48th of the shares subject to the option vested and will vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.
(8)One quarter of the total shares vested on January 29, 2021 and 1/48th of the shares subject to the option vested and will vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.
(9)One quarter of the total shares will vest on July 6, 2021 and 1/48th of the shares subject to the option will vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.
(10)4,500 of the shares subject to this RSU award vested on each of January 27, 2018, January 27, 2019, January 27, 2020 and January 27, 2021.
(11)11,106 of the shares subject to this RSU award vested on each of January 19, 2019, January 19, 2020 and January 19, 2021. An additional 11,106 of the shares subject to this RSU award will vest on January 19, 2022, subject to executive’s continued employment on the applicable vesting date.
(12)37,500 of the shares subject to this RSU award vested on each of June 1, 2019 and June 1, 2020. An additional 37,500 of the shares subject to this RSU award will vest on each of June 1, 2021 and June 1, 2022, subject to executive’s continued employment on each applicable vesting date.
(13)12,000 of the shares subject to this RSU award vested on each of February 4, 2019 and February 4, 2020. An additional 12,000 of the shares subject to this RSU award will vest on each of February 4, 2021 and February 4, 2022, subject to executive’s continued employment on each applicable vesting date.
(14)12,500 of the shares subject to this RSU award vested on August 6, 2020. An additional 12,500 of the shares subject to this RSU award will vest on each of August 6, 2021, August 6, 2022 and August 6, 2023, subject to executive’s continued employment on each applicable vesting date.
(15)10,000 of the shares subject to this RSU award vested on January 29, 2021. An additional 10,000 of the shares subject to this RSU award will vest on January 29, 2022, January 29, 2023 and January 29, 2024, subject to executive’s continued employment on each applicable vesting date.
(16)The shares subject to this PRSU vested in full on February 25, 2021, upon the achievement of the requisite milestones relating to total sales, AlloSure volume and Adjusted EBITDA.
(17)10,000 of the shares subject to this RSU award will vest on each of July 6, 2021, July 6, 2022, July 6, 2023 and July 6, 2024, subject to executive’s vesting continued employment on each applicable date.
(18)The unvested portion of this option was forfeited on December 31, 2020 as Mr. Bell resigned effective December 31, 2020.
(19)The shares subject to this RSU award were forfeited on December 31, 2020 as Mr. Bell resigned effective December 31, 2020.
(20)The shares subject to this PRSU were forfeited on December 31, 2020 as Mr. Bell resigned effective December 31, 2020.
(21)One quarter of the total shares vested on November 26, 2019, and 1/48th of the shares subject to the option vested and will vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.
(22)One quarter of the total shares will vest on November 1, 2021, and 1/48th of the shares subject to the option will vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.
(23)12,500 of the shares subject to this RSU award vested on November 26, 2020 and an additional 12,500 shares subject to this RSU award will vest on each of November 26, 2021 and November 26, 2022, subject to executive’s continued employment on each applicable vesting date.
(24)1,250 of the shares subject to this RSU award vested on August 6, 2020. An additional 1,250 of the shares subject to this RSU award will vest on each of August 6, 2021, August 6, 2022 and August 6, 2023, subject to executive’s continued employment on each applicable vesting date.
(25)5,000 of the shares subject to this RSU award vested January 29, 2021. An additional 5,000 of the shares subject to this RSU award will vest on each of January 29, 2022, January 29, 2023 and January 29, 2024, subject to executive’s continued employment on each applicable vesting date.(26) The shares subject to this PRSU vested in full on February 25, 2021, upon the achievement of the requisite milestones relating to total sales, AlloSure volume and Adjusted EBITDA.
(27)1,525 of the shares subject to this RSU award will vest on each of November 1, 2021, November 1, 2022, November 1, 2023 and November 1, 2024, subject to executive’s continued employment on each applicable vesting date.
(28)The shares subject to this PRSU shall vest upon the achievement of certain milestones relating to total sales.
(29)One quarter of the total shares vested on March 30, 2018 and 1/48th of the shares subject to the option vested and will vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.
(30)One quarter of the total shares vested on June 9, 2018 and 1/48th of the shares subject to the option vested and will vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.
(31)12,500 of the shares subject to this RSU award vested on each of June 21, 2019 and June 1, 2020. An additional 12,500 of the shares subject to this RSU award will vest on each of June 1, 2021 and June 1, 2022, subject to executive’s continued employment on each applicable vesting date.
(32)2,000 of the shares subject to this RSU award vested on each of February 4, 2019, February 4, 2020 and February 4, 2021. An additional 2,000 of the shares subject to this RSU award will vest on February 4, 2022, subject to executive’s continued employment on the applicable vesting date.
(33)625 of the shares subject to this RSU award vested on August 6, 2020. An additional 625 of the shares subject to this RSU award will vest on each of August 6, 2021, August 6, 2022 and August 6, 2023, subject to executive’s continued employment on each applicable vesting date.
(34)2,000 of the shares subject to this RSU award vested on January 29, 2021. An additional 2,000 of the shares subject to this RSU award will vest on each of January 29, 2022, January 29, 2023 and January 29, 2024, subject to executive’s continued employment on each applicable vesting date.
(35)The shares subject to this PRSU vested in full on February 25, 2021, upon the achievement of the requisite milestones relating to total sales, AlloSure volume and Adjusted EBITDA.
(36)625 of the shares subject to this RSU award vested on July 6, 2021. An additional 625 of the shares subject to this RSU award will vest on each of July 6, 2022, July 6, 2023 and July 6, 2024, subject to executive’s continued employment on each applicable vesting date.
(37)One quarter of the total shares vested on August 20, 2019, and 1/48th of the shares subject to the option vested and will vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.
(38)One quarter of the total shares vested on April 1, 2020, and 1/48th of the shares subject to the option vested and will vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.
(39)One quarter of the total shares shall vest on April 1, 2021, and 1/48th of the shares subject to the option will vest each month thereafter, subject to executive’s continued employment on each applicable vesting date.
(40)One quarter of the total shares shall vest on July 6, 2021, and 1/48th of the shares subject to the option will vest each month thereafter, subject to executive’s continued employment on each applicable vesting date
(41)1,325 of the shares subject to this RSU award vested on each of September 1, 2019 and September 1, 2020. An additional 1,325 of the shares subject to this RSU award will vest on each of September 1, 2021 and September 1, 2021, subject to executive’s continued employment on each applicable vesting date.
(42)500 of the shares subject to this RSU award vested on April 1, 2020. An additional 500 of the shares subject to this RSU award will vest on each of April 1, 2021, April 1, 2022 and April 1, 2023, subject to executive’s continued employment on each applicable vesting date.
(43)1,000 of the shares subject to this RSU award will vest on each of April 1, 2021, April 1, 2022, April 1, 2023 and April 1, 2024, subject to executive’s continued employment on each applicable vesting date.
(44)250 of the shares subject to this RSU award will vest on each of July 6, 2021, July 6, 2022, July 6, 2023 and July 6, 2024, subject to executive’s continued employment on each applicable vesting date.
(45)All shares subject to this RSU award will vest on December 10, 2021, subject to executive’s continued employment on such vesting date.
Option Exercises and Stock Vested
The following table presents, for each of the named executive officers, the number of shares of our common stock acquired upon the exercise of stock options and the vesting and settlement of RSUs during 2020 and the aggregate value realized upon the exercise of stock options and the vesting and settlement of RSUs.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Option Awards | | Stock Awards |
| Name | | Number of Shares Acquired on Exercise (#) | | Value Realized on Exercise | | Number of Shares Acquired on Vesting (#) | | Value Realized on Vesting |
| Peter Maag, Ph.D. | | 109,267 | | | $ | 3,955,742 | | | 58,419 | | (1) | | $ | 1,715,434 | | (1) |
| Reginald Seeto, MBBS | | — | | | $ | — | | | 29,750 | | | | $ | 1,103,433 | | |
| Sasha King | | 51,181 | | | $ | 1,634,236 | | | 23,125 | | | | $ | 654,806 | | |
Michael Bell(2) | | 61,456 | | | $ | 1,608,505 | | | 37,254 | | | | $ | 982,092 | | |
Marcel Konrad(3) | | 10,833 | | | $ | 77,538 | | | 3,825 | | | | $ | 99,392 | | |
(1)In accordance with our RSU and performance unit deferral election program, Dr. Maag elected to defer the settlement of 12,000 shares of common stock upon vesting of an RSU that vested on January 25, 2020, 48,000 shares of common stock upon vesting of an RSU that vested on February 27, 2020, and 12,500 shares of common stock upon vesting of an RSU that vested on August 6, 2020. The vesting date value of shares subject to the RSU that otherwise would have been delivered if not deferred on January 25, 2020 was $260,040. The vesting date value of shares subject to the RSU that otherwise would have been delivered if not deferred on February 27, 2020 was $1,077,360. The vesting date value of shares subject to the RSU that otherwise would have been delivered if not deferred on August 6, 2020 was $433,125. See “—Non-Qualified Deferral Compensation Plan” below.
(2)Mr. Bell resigned effective December 31, 2020.
(3)Mr. Konrad was appointed as our Interim Chief Financial Officer effective December 31, 2020 and served in this role until March 25, 2021.
Pension Benefits
No pension benefits were paid to any of our named executive officers during fiscal 2020.
Non-Qualified Deferred Compensation Plan
In December 2018, our Compensation Committee approved an RSU and performance unit deferral election program, which is still in effect, pursuant to which our non-employee directors, executive officers and certain other employees may elect, on an annual basis, to defer the settlement of all RSU and performance unit awards granted to such individuals until the first to occur of (i) a “change in control,” as defined in our 2014 Plan, (ii) the individual’s death, or (iii) a specified number of years following the individual’s separation of service with us, in which case the shares will settle in a number of substantially equal annual installments selected by the individual, on every June 30 starting in the calendar year immediately following the year in which the individual incurs a separation of service. We do not otherwise contribute to the RSU and performance unit deferral election program and the amount a participant receives at the end of a deferral period is based solely on the value of our stock at the end of the deferral period.
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| Name | | Executive Contributions in Last Fiscal Year(1) | | Aggregate Earnings in Last Fiscal Year(2) | | Aggregate Distributions in Last Fiscal Year | | Aggregate Balance at Last Fiscal Year End |
| Peter Maag, Ph.D. | | $ | 1,770,525 | | | 3,482,100 | | | — | | | — | |
(1)Represents the vesting date value of RSUs that otherwise would have been delivered if not deferred.
(2)The aggregate value of the deferred RSUs as of December 31, 2020 was $5,252,625.
Equity Compensation Plan Information
The following table provides information as of December 31, 2020 with respect to shares of our common stock that may be issued under our existing equity compensation plans.
| | | | | | | | | | | | | | | | | | | | |
| Plan Category | | (a) Number of Securities to be Issued Upon Exercise of Outstanding Options and Rights | | (b) Weighted Average Exercise Price of Outstanding Options and Rights(1) | | (c) Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) |
| Equity compensation plans approved by stockholders(2) | | 4,458,222 | | | $ | 21.92 | | | 513,437 | |
| Equity compensation plans not approved by stockholders(3) | | 91,042 | | | $ | 21.74 | | | 159,531 | |
| Total: | | 4,549,264 | | | $ | 21.92 | | | 672,968 | |
(1)The weighted average exercise price is calculated based solely on outstanding stock options and does not reflect the shares that will be issued upon the vesting of outstanding awards of RSUs, which have no exercise price.
(2)Includes the following plans: CareDx, Inc. 1998 Equity Incentive Plan, CareDx, Inc. 2008 Equity Incentive Plan, ImmuMetrix 2013 Equity Incentive Plan, the 2014 Plan and the CareDx, Inc. 2014 Employee Stock Purchase Plan (“ESPP”). Our 2014 Plan provides that on the first day of each fiscal year beginning in 2015, the number of shares available for issuance thereunder is automatically increased by a number equal to the least of (i) four percent (4.0%) of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year, or (ii) such other amount as may be determined by our Board of Directors. Our ESPP provides that on the first day of each fiscal year beginning in 2015, the number of shares available for issuance thereunder is automatically increased by a number equal to the least of (i) 133,900 shares of common stock, (ii) one and one-half percent (1.5%) of the outstanding shares of Common Stock on the last day of the immediately preceding fiscal year, or (iii) such other amount as may be determined by our Board of Directors. On January 1, 2021, the number of shares available for issuance under our 2014 Plan and our ESPP increased by 1,977,646 shares and 133,900 shares, respectively, pursuant to these provisions. These increases are not reflected in the table above.
(3)Consists of shares available for issuance under the CareDx, Inc. 2016 Inducement Equity Incentive Plan and the CareDx, Inc. 2019 Inducement Equity Incentive Plan.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information with respect to the beneficial ownership of our common stock as of March 31,
20192021 for:
•each of our current directors and nominees for director;
•each of our named executive officers;
•all of our current directors and executive officers as a group; and
•each person or group who beneficially owned more than 5% of our common stock.
We have determined beneficial ownership in accordance with the rules of the SEC and the information is not necessarily indicative of beneficial ownership for any other purpose. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject to community property laws where applicable.
We have based our calculation of the percentage of beneficial ownership on
41,812,65351,936,777 shares of our common stock outstanding as of March 31,
2019.2021. We have deemed shares of our common stock subject to warrants or stock options that are currently exercisable or exercisable within 60 days of March 31,
2019,2021, or issuable pursuant to RSUs that are subject to vesting conditions expected to occur within 60 days of March 31,
2019,2021, to be outstanding and to be beneficially owned by the person holding the warrants, stock option or RSUs for the purpose of computing the percentage ownership of that person. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person.
Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o CareDx, Inc., 3260 Bayshore1 Tower Place, 9th Floor, South San Francisco, CA 94080.
| | | | | | | | | | | | | | |
| Name of Beneficial Owner | | Number of
Shares Beneficially Owned | | Percentage of Shares Beneficially Owned |
| 5% Stockholders: | | | | |
Entities affiliated with Alger Associates, Inc.(1) | | 5,353,953 | | | 10.3 | % |
ARK Investment Management LLC(2) | | 5,192,563 | | | 10.0 | % |
BlackRock, Inc.(3) | | 3,850,786 | | | 7.4 | % |
The Vanguard Group(4) | | 3,496,078 | | | 6.7 | % |
Invesco Ltd. (5) | | 3,067,175 | | | 5.9 | % |
| Directors and Named Executive Officers: | | | | |
Peter Maag, Ph.D.(6) | | 1,179,117 | | | 2.2 | % |
Michael Bell(7) | | 103,343 | | | * |
Reginald Seeto, MBBS(8) | | 237,134 | | | * |
Sasha King(9) | | 188,421 | | | * |
Marcel Konrad(10) | | 32,280 | | | * |
George W. Bickerstaff, III(11) | | 151,648 | | | * |
Grace E. Colón, Ph.D.(12) | | 16,543 | | | * |
Christine M. Cournoyer(13) | | 22,370 | | | * |
Fred E. Cohen, M.D., D. Phil(14) | | 176,796 | | | * |
Michael D. Goldberg(15) | | 224,235 | | | * |
William A. Hagstrom(16) | | 88,492 | | | * |
Ralph Snyderman, M.D.(17) | | 169,851 | | | * |
All current directors and executive officers as a group (11 persons)(18) | | 2,469,107 | | | 4.6 | % |
*Represents beneficial ownership of less than one percent (1%) of the outstanding shares of our common stock.
(1)Based on information reported on a Schedule 13G filed with the SEC on February 16, 2021, this consists of 5,353,953 shares of common stock over which Fred Alger Management, LLC (“FAM”) has sole voting and dispositive power. These shares of common stock are beneficially owned by one or more open-end investment companies or other managed accounts that are investment management clients of FAM, a registered investment adviser. FAM is a 100% owned subsidiary of Alger Group Holdings, LLC (“AGH”), a holding company. AGH is a 100% owned subsidiary of Alger Associates, Inc., a holding company. The address for each of these stockholders is 360 Park Avenue South, New York, NY 10010.
(2)ARK Investment Management LLC (“ARK”) filed a Schedule 13G on February 10, 2021, reporting that it had sole voting power with respect to 5,192,563 shares, sole dispositive power with respect to 5,192,563 shares and beneficial ownership of an aggregate of 5,192,563 shares in its capacity as an investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E) under the Exchange Act. ARK’s address is 3 East 28th Street, 7th Floor, New York, NY 10016.
(3)BlackRock, Inc. (“BlackRock”) filed a Schedule 13G/A on January 28, 2021, reporting that it had sole voting power with respect to 3,791,876 shares, sole dispositive power with respect to 3,850,786 shares and beneficial ownership of an aggregate of 3,850,786 shares in its capacity as a parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G) under the Exchange Act. BlackRock’s address is 55 East 52nd Street, New York, New York 10055.
(4)The Vanguard Group (“Vanguard”) filed a Schedule 13G/A on February 8, 2021, reporting that it had shared voting power with respect to 109,475 shares, sole dispositive power with respect to 3,349,220 shares, shared dispositive power with respect to 146,858 shares and beneficial ownership of an aggregate of 3,496,078 shares in its capacity as an investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E) under the Exchange Act. Vanguard’s address is 100 Vanguard Blvd., Brisbane, CA 94005. | | | | | | | | |
Name of Beneficial Owner | | Number of
Shares
Beneficially
Owned | | | Percentage
of
Shares
Beneficially
Owned | |
5% Stockholders: | | | | | | | | |
Entities affiliated with Alger Associates, Inc.(1) | | | 4,203,690 | | | | 10.1 | % |
Entities affiliated with Gagnon Securities LLC(2) | | | 3,450,959 | | | | 8.3 | % |
BlackRock, Inc.(3) | | | 2,491,800 | | | | 6.0 | % |
The Vanguard Group(4) | | | 2,175,503 | | | | 5.2 | % |
Directors and Named Executive Officers: | | | | | | | | |
Peter Maag, Ph.D.(5) | | | 462,279 | | | | 1.1 | % |
Reginald Seeto, MBBS | | | — | | | | * | |
Michael Bell(6) | | | 19,886 | | | | * | |
George W. Bickerstaff, III(7) | | | 142,906 | | | | * | |
Fred E. Cohen, M.D., D. Phil(8) | | | 93,840 | | | | * | |
Michael D. Goldberg(9) | | | 236,784 | | | | * | |
William A. Hagstrom(10) | | | 95,225 | | | | * | |
Ralph Snyderman, M.D.(11) | | | 131,721 | | | | * | |
All current directors and executive officers as a group (10 persons)(12) | | | 1,354,607 | | | | 3.2 | % |
* | Represents beneficial ownership of less than one percent (1%) of the outstanding shares of our common stock.
|
(1) | Based on information reported on a Schedule 13G filed with the SEC on February 14, 2019, this consists of 4,203,690 shares of common stock over which Fred Alger Management, Inc. (“FAM”) has sole voting and dispositive power. These shares of common stock are beneficially owned by one or moreopen-endMalvern, PA 19355.
|
| investment companies or other managed accounts that are investment management clients of FAM, a registered investment adviser. FAM is a 100% owned subsidiary of Fred Alger & Company, Incorporated (“FAC”) a registered broker dealer. FAC is a 100% owned subsidiary of Alger Associates, Inc., a holding company. The address for each of these stockholders is 360 Park Avenue South, New York, NY 10010. |
(2) | Based on information reported on a Schedule 13G/A filed with the SEC on November 6, 2018, this consists of (i) 398,892 shares of common stock over which Neil Gagnon has sole voting and dispositive power, (ii) 2,687,758 shares of common stock over which Neil Gagnon has shared voting power, and (iii) 3,052,067 shares of common stock over which Mr. Gagnon has shared dispositive power. Mr. Gagnon is the managing member and principal owner of Gagnon Securities LLC (“GS”), an investment adviser registered with the SEC under the Investment Advisers Act of 1940, as amended (the “Advisers Act”), and a registered broker-dealer, in its role as investment manager to several customer accounts, foundations, partnerships and trusts (collectively, the “Accounts”) to which it gives investment advice. Mr. Gagnon and GS may be deemed to share voting power with respect to 1,753,435 shares of our common stock held in the Accounts and dispositive power with respect to 1,931,125 shares of our common stock held in the Accounts. Mr. Gagnon is also the Chief Executive Officer of Gagnon Advisors, LLC (“Gagnon Advisors”), an investment adviser registered with the SEC under the Advisers Act. Mr. Gagnon and Gagnon Advisors, in its role as investment manager to Gagnon Investment Associates, LLC (“GIA”), a private investment fund, may be deemed to share voting and dispositive power with respect to the 882,943 shares of common stock held by GIA. The address for each of these stockholders is 1370 Ave. of the Americas, 24th Floor, New York, NY 10019.
|
(3) | BlackRock, Inc. (“BlackRock”) filed a Schedule 13G on February 8, 2019, reporting that it had sole voting power with respect to 2,418,788 shares and sole dispositive power with respect to 2,491,800 shares, in its capacity as a parent holding company or control person in accordance with Rule(5)Invesco Ltd. (“Invesco”) filed a Schedule 13G on February 16, 2021, reporting that it had sole voting power with respect to 2,951,234 shares, sole dispositive power with respect to 3,067,175 shares and beneficial ownership of an aggregate of 3,067,175 shares in its capacity as an investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E) under the Exchange Act and a parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G). Invesco’s address is 1555 Peachtree Street NE, Suite 1800, Atlanta, GA 30309. under the Exchange Act. BlackRock’s address is 55 East 52nd Street, New York, New York 10055
|
(4) | The Vanguard Group (“Vanguard”) filed a Schedule 13G on February 11, 2019, reporting that it had sole voting power with respect to 69,780 shares, shared voting power with respect to 2,072 shares, sole dispositive power with respect to 2,106,590 shares, shared dispositive power with respect to 68,913 shares and beneficial ownership of an aggregate of 2,175,503 shares in its capacity as an investment adviser in accordance with Rule13d-1(b)(1)(ii)(E) under the Exchange Act. Vanguard’s address is 100 Vanguard Blvd., Malvern, PA 19355.
|
(5) | Represents 318,025 shares of common stock held by Dr. Maag and 144,704 shares subject to options that are immediately exercisable or exercisable within 60 days of March 31, 2019.
|
(6) | Represents 13,280 shares of common stock held by Mr. Bell and 6,606 shares subject to options that are immediately exercisable or exercisable within 60 days of March 31, 2019.
|
(7) | Represents 81,967 shares of common stock held by Mr. Bickerstaff and 60,939 shares subject to options that are immediately exercisable or exercisable within 60 days of March 31, 2019.
|
(8) | Represents 47,901 shares of common stock held by Dr. Cohen and 45,939 shares subject to options that are immediately exercisable or exercisable within 60 days of March 31, 2019.
|
(9) | Represents 80,546 shares of common stock held by Mr. Goldberg and 156,238 shares subject to options that are immediately exercisable or exercisable within 60 days of March 31, 2019.
|
(10) | Represents 35,272 shares of common stock held by Mr. Hagstrom and 59,953 shares subject to options that are immediately exercisable or exercisable within 60 days of March 31, 2019.
|
(11) | Represents 56,184 shares of common stock held by Dr. Snyderman, and 75,537 shares subject to options that are immediately exercisable or exercisable within 60 days of March 31, 2019.
|
(12) | Comprised of shares included under “Directors and Named Executive Officers”, plus 39,546 shares of common stock owned directly by our two other executive officers and options to purchase an aggregate of 131,970 shares of common stock held by our two other executive officers that are immediately exercisable or exercisable within 60 days of March 31, 2019.
|
(6)Represents 422,968 shares of common stock held by Dr. Maag and 756,149 shares subject to options that are immediately exercisable or exercisable within 60 days of March 31, 2021.
(7)Mr. Bell resigned effective December 31, 2020.
(8)Represents 142,634 shares of common stock held by Dr. Seeto and 94,500 shares subject to options that are immediately exercisable or exercisable within 60 days of March 31, 2021.
(9)Represents 53,561 shares of common stock held by Ms. King and 134,860 shares subject to options that are immediately exercisable or exercisable within 60 days of March 31, 2021.
(10)Represents 13,864 shares of common stock held by Mr. Konrad and 16,916 shares subject to options that are immediately exercisable or exercisable within 60 days of March 31, 2021 and 1,500 RSUs vesting within 60 days of March 31, 2021.
(11)Represents 80,745 shares of common stock held by Mr. Bickerstaff and 70,903 shares subject to options that are immediately exercisable or exercisable within 60 days of March 31, 2021.
(12)Represents 7,967 shares of common stock held by Dr. Colón and 8,576 shares subject to options that are immediately exercisable or exercisable within 60 days of March 31, 2021.
(13)Represents 12,085 shares of common stock held by Ms. Cournoyer and 10,285 shares subject to options that are immediately exercisable or exercisable within 60 days of March 31, 2021.
(14)Represents 105,893 shares of common stock held by Dr. Cohen and 70,903 shares subject to options that are immediately exercisable or exercisable within 60 days of March 31, 2021.
(15)Represents 58,033 shares of common stock held by Mr. Goldberg and 166,202 shares subject to options that are immediately exercisable or exercisable within 60 days of March 31, 2021.
(16)Represents 18,575 shares of common stock held by Mr. Hagstrom and 69,917 shares subject to options that are immediately exercisable or exercisable within 60 days of March 31, 2021.
(17)Represents 72,672 shares of common stock held by Dr. Snyderman, and 97,179 shares subject to options that are immediately exercisable or exercisable within 60 days of March 31, 2021.
(18)Comprised of shares included under “Directors and Named Executive Officers”, excluding Mr. Bell, as he resigned effective December 31, 2020, and Mr. Konrad who is no longer an executive officer, plus 14,500 shares of common stock held by one of our other executive officers.
RELATED
PERSONPARTY TRANSACTIONS
The following is a description of
Since January 1, 2020 there have not been any transactions or series of transactions,
since January 1, 2018, or anyand there is currently
no proposed transaction, to which we were or are to be a participant in which the amount involved in the transaction or series of transactions exceeds $120,000, and in which any of our directors, executive officers or persons who we know held more than five percent of any class of our capital stock, including their immediate family members, had or will have a direct or indirect material interest, other than compensation arrangements that are described under “Executive Compensation”
above.Investors’ Rights Agreement
We are party to an investors’ rights agreement which provides, among other things, that certain holders of our common stock haveabove and the right to demand that we file a registration statement or request that their shares of our common stock be covered by a registration statement that we are otherwise filing.
indemnification agreements described below.
Indemnification Agreements
We have also entered into indemnification agreements with our directors and certain of our executive officers. The indemnification agreements and our
certificateCertificate of
incorporationIncorporation and
amended and restated bylawsBylaws require us to indemnify our directors and officers to the fullest extent permitted by Delaware law.
Policies and Procedures for Related Party Transactions
Our Audit Committee adopted a formal written policy that our Audit Committee is responsible for reviewing “related party transactions.” A “related
personparty transaction” is a transaction, arrangement, or relationship in which we (including any of our subsidiaries) and any “related
person”party” were, are, or will be participants involving an amount that exceeds $120,000. For purposes of this policy, a related
personparty is defined as a director, nominee for director, executive officer, or greater than 5% beneficial owner of our common stock and their immediate family members, any entity in which such person is employed or is a general partner or principal and any entity where such person has a 5% or greater beneficial ownership interest.
Under this policy, all related party transactions may be consummated or continued only if approved or ratified by our Audit Committee. In determining whether to approve or ratify any such proposal, our Audit Committee will take into account, among other factors it deems appropriate, (a) whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances, and (b) the extent of the related party’s interest in the transaction. The policy grants standingpre-approval of certain transactions, including (1) certain compensation arrangements of executive officers, (2) certain director compensation arrangements, (3) transactions with another company at which a related party’s only relationship is as anon-executive employee, director or beneficial owner of less than 5% of that company’s shares, (4) transactions where a related party’s interest arises solely from the ownership of our common stock and all holders of our common stock received the same benefit on a pro rata basis, and (5) transactions available to all U.S. employees generally.
Delinquent Section 16(a)
Beneficial Ownership Reporting ComplianceReports
Section 16(a) of the Exchange Act requires that our executive officers and directors, and persons who own more than 10% of our common stock, file reports of ownership and changes of ownership with the SEC. Such directors, executive officers and 10% stockholders are required by SEC regulation to furnish us with copies of all Section 16(a) forms they file.
SEC regulations require us to identify in this proxy statement anyone who failed to file a timely required report during the most recent fiscal year. Based solely upon our review of forms we received, or written representations from reporting persons stating that they were not required to file these forms, we believe that during our fiscal year ended December 31,
2018,2020, all Section 16(a) filing requirements were satisfied on a timely basis, except
(i)for one Form 4 for each of
Peter Maag, Ph.D., Michael Bell, James Yee, M.D., Ph.D., Anders Karlsson, Sasha King and Mitchell J. Nelles, Ph.D., which were due January 23, 2018, but were inadvertently filed late on January 25, 2018, (ii) one Form 4/A for each of Peter Maag, Ph.D. and Mitchell J. Nelles, Ph.D., which were due January 24, 2018, but were inadvertently filed late on January 25, 2018, (iii) one Form 4/A for each of Peter Maag, Ph.D., Michael Bell, James Yee, M.D., Ph.D., Sasha King and Mitchell J. Nelles, Ph.D., which were due July 3, 2018, but were inadvertently filed late on July 12, 2018, (iv) one Form 4 for each of Fred E. Cohen, M.D., D. Phil.,George W. Bickerstaff, Christine M. Cournoyer, Ralph Snyderman, M.D.
, George W. Bickerstaff, William A. Hagstrom and Michael D. Goldberg, which were due on
June 22, 2018,April 3, 2020, but were inadvertently filed late on July
3, 2018 and (v) one Form 5 for Ralph Snyderman, M.D. which was due on February 14, 2019, but was inadvertently filed late on February 22, 2019.6, 2020.
Our financial statements for our fiscal year ended December 31, 20182020 are included in our Annual Report onForm 10-K for the year ended December 31, 2018.2020. This proxy statement and our annual report are posted on the Investor Relations section of our website at investors.caredxinc.com and are available from the SEC at its website at www.sec.gov.www.sec.gov. You may also obtain a copy of our annual report without charge by sending a written request to CareDx, Inc., Attention: Investor Relations, 3260 Bayshore Blvd., Brisbane, California 94005.1 Tower Place, 9th Floor, South San Francisco, CA 94080.
Note About Forward-Looking Statements
This proxy statement contains forward-looking statements that involve a number of risks and uncertainties. Words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in our Annual Report on Form 10-K for the year ended December 31, 2020. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this proxy statement may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.
Householding
The SEC has adopted rules that permit companies and intermediaries to satisfy the delivery requirements for Notice of Internet Availability of Proxy Materials (the “Notice”)or other proxy materials with respect to two or more stockholders sharing the same address by delivering a single notice or other annual meeting materials addressed to those stockholders. This process, which is commonly referred to as householding, potentially provides extra convenience for stockholders and cost savings for companies. Stockholders who participate in householding will continue to be able to access and receive separate proxy cards.
A Notice will be delivered in one single envelope to multiple stockholders sharing an address unless contrary instructions have been received from one or more of the affected stockholders. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate Notice or other proxy materials, please notify your broker or call the Company’s Secretary at (415) 287-2300 or submit a request in writing to our Corporate Secretary, 1 Tower Place, 9th Floor, South San Francisco, CA 94080. Stockholders who currently receive multiple copies of the Notice or other proxy materials at their address and would like to request householding of their communications should contact their broker. In addition, we will promptly deliver, upon written or oral request to the address or telephone number above, a separate copy of the Notice or other proxy materials to a stockholder at a shared address to which a single copy of the documents was delivered.
We maintain a website at www.caredx.com.www.caredx.com. Information contained on, or that can be accessed through, our website is not intended to be incorporated by reference into this proxy statement, and references to our website address in this proxy statement are inactive textual references only. Our Board of Directors does not know of any other matters to be presented at the Annual Meeting. If any additional matters are properly presented at the Annual Meeting, the persons named on the enclosed proxy card will have discretion to vote the shares of common stock they represent in accordance with their own judgment on such matters.
It is important that your shares of common stock be represented at the Annual Meeting, regardless of the number of shares that you hold. You are, therefore, urged to vote over the Internet or by telephone as instructed on the proxy card or execute and return, at your earliest convenience, the proxy card.
| | | | |
| | THE BOARD OF DIRECTORS | | |
| | |
| | Brisbane, California | | |
| | |
| | April 30, 2019 | | |
THE BOARD OF DIRECTORS
South San Francisco, California
April [●], 2021
ENDORSEMENT_LINE 000004 MR
54
Appendix A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 C123456789 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext Your vote matters – here’s how
Proposed Amendments to vote! You may vote online orAmended and Restated Certificate of Incorporation
The following language shows the changes to the Certificate of Incorporation that would result from the proposed amendments to eliminate supermajority voting provisions relating to amendments to the Certificate of Incorporation and the Bylaws, if approved, with deletions indicated by phone instead strikethroughs and additions indicated by underlining.
ARTICLE VI
In furtherance and not in limitation of mailing this card. Votes submitted electronically must be receivedthe powers conferred by 11:59 p.m., Pacific Time, on June 16, 2019. Online Go to www.envisionreports.com/CDNA or scanstatute, the QR code — login details are located in the shaded bar below. Phone Call toll free1-800-652-VOTE (8683) within the USA, US territories and Canada Save paper, time and money! Sign up for electronic delivery at www.envisionreports.com/CDNA Using a black ink pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas. 2019 Annual Meeting Proxy Card 1234 5678 9012 345 IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. A Proposals — The Board of Directors recommends a vote FOR all of the nominees listed in Proposal 1 and FOR Proposal 2. 1. ElectionCorporation is expressly authorized to adopt, amend or repeal the Bylaws of Directors: For Withhold For Withhold 01 - Fred E. Cohen, M.D., D. Phil 02 - William A. Hagstrom For Against Abstain 2. To ratify the appointmentCorporation by the affirmative vote of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2019. B Authorized Signatures — This section must be completed for your vote to count. Please date and sign below. Please sign exactly as name(s) appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, corporate officer, trustee, guardian, or custodian, please give full title. Date (mm/dd/yyyy) — Please print date below. Signature 1 — Please keep signature withina majority of the box. Signature 2 — Please keep signature within the box. 0326IA C 1234567890 J N T 21BV 419043 MR A SAMPLE (THIS AREA IS SET UP TO ACCOMMODATE 140 CHARACTERS) MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND
2019 Annual Meeting Admission Ticket 2019 Annual MeetingWhole Board. Notwithstanding any other provision of CareDx, Inc. Stockholders June 17, 2019, 10:00am PST CareDx, Inc. Headquarters 3260 Bayshore Blvd., Brisbane, CA 94005 Small steps make an impact. Help the environment by consenting to receive electronic delivery, sign up at www.envisionreports.com/CDNA IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. Proxy — CareDx, Inc. + Noticethis Certificate of 2019 Annual Meeting of Stockholders Proxy Solicited by Board of Directors for Annual Meeting — Monday, June 17, 2019 Peter Maag and Michael Bell,Incorporation or any provision of them,law that might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any series of Preferred Stock required by law, by this Certificate of Incorporation or by any Preferred Stock Designation, the affirmative vote of the holders of at least 66 2/3%a majority of the total voting power of the stock outstanding voting securities of the Corporation, voting together as a single class,entitled to vote thereon shall be required for the stockholders of the Corporation to amend, alter or repeal the Bylaws or adopt new Bylaws.
ARTICLE IX
If any provision or provisions of this Certificate of Incorporation shall be held to be invalid, illegal or unenforceable as applied to any circumstance for any reason whatsoever: (i) the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Certificate of Incorporation (including, without limitation, each portion of any paragraph of this Certificate of Incorporation containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and (ii) to the fullest extent possible, the provisions of this Certificate of Incorporation (including, without limitation, each such portion of any paragraph of this Certificate of Incorporation containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to permit the Corporation to protect its directors, officers, employees and agents from personal liability in respect of their good faith service or for the benefit of the Corporation to the fullest extent permitted by law.
The Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation (including any rights, preferences or other designations of Preferred Stock), in the manner now or hereafter prescribed by this Certificate of Incorporation and the DGCL; and all rights, preferences and privileges herein conferred upon stockholders by and pursuant to this Certificate of Incorporation in its present form or as hereafter amended are granted subject to the right reserved in this Article IX. Notwithstanding any other provision of this Certificate of Incorporation, and in addition to any other vote that may be required by law or the terms of any series of Preferred Stock, the affirmative vote of the holders of at least 66 2/3%a majority of the voting power of all then outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend, alter or repeal, or adopt any provision as part of this Certificate of Incorporation inconsistent with the purpose and intent of, Article V, Article VI, Article VII, Article VIII or this Article IX (including, without limitation, any such Article as renumbered as a result of any amendment, alteration, change, repeal or adoption of any other Article).
Appendix B
Proposed Amendments to Bylaws
The following language shows the changes to the Bylaws that would result from the proposed amendments to eliminate supermajority voting provisions relating to amendments to the Certificate of Incorporation and the Bylaws, if approved, with deletions indicated by strikethroughs and additions indicated by underlining.
ARTICLE X — AMENDMENTS
These bylaws may be adopted, amended or repealed by the affirmative vote of the holders of at least 66 2/3%a majority of the total voting power of substitution, are hereby authorized to represent andoutstanding voting securities, voting together as a single class. The board of directors, acting by the affirmative vote the sharesof a majority of the undersigned, with allWhole Board, shall also have the powerspower to adopt, amend or repeal bylaws; provided, however, that a bylaw amendment adopted by stockholders which specifies the undersigned would possess if personally present, atvotes that shall be necessary for the Annual Meetingelection of Stockholders of CareDx, Inc. todirectors shall not be held on June 17, 2019further amended or at any postponement or adjournment thereof. Shares represented by this proxy will be votedrepealed by the stockholder. If no such directions are indicated, the Proxies will have authority to vote FOR all nominees in Proposal 1 and FOR Proposal 2. In their discretion, the Proxies are authorized to vote upon such other business as may properly come before the meeting. This proxy is governed by the lawsboard of the State of Delaware. (Items to be voted appear on reverse side) Cdirectors.
Non-Voting
Items Change of Address — Please print new address below. Comments — Please print your comments below.
